

1     **Direct capsid labeling of infectious HIV-1 by genetic code expansion allows**  
2     **detection of largely complete nuclear capsids and suggests nuclear entry of**  
3             **HIV-1 complexes via common routes**

4

5

6     Sandra Schifferdecker<sup>1</sup>, Vojtech Zila<sup>1</sup>, Thorsten G. Müller<sup>1</sup>, Volkan Sakin<sup>1</sup>, Maria  
7     Anders-Össwein<sup>1</sup>, Vibor Laketa<sup>1,2</sup>, Hans-Georg Kräusslich<sup>1,2</sup>, Barbara Müller<sup>1\*</sup>

8

9     <sup>1</sup> Department of Infectious Diseases, Virology, University Hospital Heidelberg,  
10     Heidelberg, Germany

11     <sup>2</sup> German Center for Infection Research, partner site Heidelberg, Germany

12

13     \*To whom correspondence should be addressed: [Barbara.mueller@med.uni-](mailto:Barbara.mueller@med.uni-heidelberg.de)  
14     [heidelberg.de](mailto:Barbara.mueller@med.uni-heidelberg.de)

15

16

17

18     **Keywords:** HIV-1, capsid, click labeling, amber suppression, genetic code  
19     expansion, primary CD4<sup>+</sup> T cells, electron microscopy, correlative microscopy, STED,  
20     super-resolution microscopy

21 **Abstract**

22 The cone-shaped mature HIV-1 capsid is the main orchestrator of early viral  
23 replication. After cytosolic entry, it transports the viral replication complex along  
24 microtubules towards the nucleus. Capsid uncoating from the viral genome apparently  
25 occurs beyond the nuclear pore. Observation of post-entry events *via* microscopic  
26 detection of HIV-1 capsid protein (CA) is challenging, since epitope shielding limits  
27 immunodetection, and the genetic fragility of CA hampers other labeling  
28 approaches. Here, we present a minimally invasive strategy based on genetic code  
29 expansion and click chemistry that allows for site-directed fluorescent labeling of HIV-  
30 1 CA, while retaining virus morphology and infectivity. Thereby, we could directly  
31 visualize virions and subviral complexes using advanced microscopy, including  
32 nanoscopy and correlative imaging. Quantification of signal intensities of subviral  
33 complexes showed that the amount of CA associated with nuclear complexes in HeLa-  
34 derived cells and primary T cells is consistent with a complete capsid and revealed that  
35 treatment with the small molecule inhibitor PF74 did not result in capsid dissociation  
36 from nuclear complexes. Cone-shaped objects detected in the nucleus by electron  
37 tomography were clearly identified as capsid-derived structures by correlative  
38 microscopy. High-resolution imaging revealed dose-dependent clustering of nuclear  
39 capsids, suggesting that incoming particles may follow common entry routes.

40

## 41 **Introduction**

42 The cone-shaped capsid that encases the viral RNA genome and replication proteins  
43 is a characteristic feature of infectious human immunodeficiency virus type 1 (HIV-1)  
44 particles. Data obtained by many research groups over the past decade have revised  
45 our understanding of the role of the mature capsid in HIV-1 replication, placing this  
46 structure at the center stage of post-entry replication steps (reviewed in Campbell and  
47 Hope, 2015; Novikova *et al.*, 2019; Engelman, 2021; Guedán *et al.*, 2021; Toccafondi,  
48 Lener and Negroni, 2021). Upon fusion of the virion envelope with the cell membrane,  
49 the capsid, which consists of ~1,200-1,500 monomers of the capsid protein CA (Briggs  
50 *et al.* 2003), is released into the cytosol. It then usurps host cell factors to traffic towards  
51 the nucleus. Reverse transcription of the viral RNA into dsDNA is initiated during  
52 passage of the subviral structure through the cytosol. Following import into the nucleus,  
53 the viral dsDNA is covalently integrated into the host cell genome by the viral integrase.  
54 Prior to integration, the surrounding capsid shell needs to expose the dsDNA in a  
55 process termed uncoating. However, the precise mechanisms, location, and timing of  
56 capsid uncoating are still under investigation.

57 Initially, the HIV-1 capsid was presumed to rapidly dissociate upon cell entry, based  
58 on its instability observed in early biochemical analyses (Miller, Farnet, and Bushman  
59 1997; Bukrinsky *et al.* 1993; Fassati and Goff 2001). Rapid or gradual disassembly in  
60 the cytosol was also supported by several studies applying fluorescence imaging to  
61 analyze subviral complexes in infected cells (Hulme, Perez and Hope, 2011; Xu *et al.*,  
62 2013; Cosnefroy, Murray and Bishop, 2016; Mamede *et al.*, 2017). However, the  
63 finding that CA, or even the capsid lattice, directly interacts with various host factors  
64 involved in post-entry replication steps - including not only cytosolic proteins but also  
65 nucleoporins and even the nuclear protein CPSF6 (e.g., Schaller *et al.*, 2011; Price *et al.*  
66 *et al.*, 2012; Di Nunzio *et al.*, 2013; Matreyek *et al.*, 2013; Bhattacharya *et al.*, 2014; Lelek  
67 *et al.*, 2015; Rebensburg *et al.*, 2021) - implicated involvement of at least a partial  
68 lattice structure in later stages of post-entry replication. Furthermore, increasing  
69 evidence from imaging-based analyses argued for capsid uncoating at the nuclear  
70 pore (Arhel *et al.* 2007; Burdick *et al.* 2017; Rodriguez, Lester, and Dougherty 2007;  
71 Francis *et al.* 2016; Francis and Melikyan 2018; Francis, Marin, Prellberg, *et al.* 2020;  
72 Rasaiyaah *et al.* 2013), or even for the passage of capsids or capsid-related structures  
73 through nuclear pores (Zila *et al.* 2021; Selyutina *et al.* 2020; T. G. Müller *et al.* 2021;  
74 Dharan *et al.* 2020; Burdick *et al.* 2020). The recent detection of cone-shaped objects

75 in the nuclear pore channel and inside the nucleus by correlative light and electron  
76 microscopy (CLEM), and intranuclear separation of CA or IN from reverse transcribed  
77 dsDNA also support the model that the nucleus is the site of HIV-1 uncoating (Li et al.  
78 2021; Burdick et al. 2020; Zila et al. 2021; T. G. Müller et al. 2021).

79 One explanation for apparent discrepancies between different studies are the methods  
80 that have been used for CA detection in fluorescence microscopy. Since the  
81 modification of CA by genetic labeling strategies proved to be challenging, most studies  
82 applied immunofluorescence (IF) staining or other indirect labeling approaches  
83 (Francis et al. 2016; Francis and Melikyan 2018; Francis, Marin, Prellberg, et al. 2020;  
84 Márquez et al. 2018; Mamede et al. 2017; Hulme, Perez, and Hope 2011; Hulme and  
85 Hope 2014). A limitation of IF is that staining efficiency may vary substantially  
86 depending on the antibody and detection conditions used, as well as on differential  
87 exposure or shielding of epitopes due to conformational changes or different  
88 intracellular environments. We could indeed show previously that immunostaining  
89 efficiency of CA in the nucleus of host cells strongly depends on cell type and  
90 experimental conditions (T. G. Müller et al. 2021). Furthermore, IF is incompatible with  
91 live cell analyses. Infectious HIV-1 derivatives carrying fluorescent CA would resolve  
92 these limitations and allow the direct observation of entering capsids with quantitative  
93 analyses.

94 However, viral capsid proteins are intrinsically challenging targets for genetic labeling.  
95 They are generally small proteins that need to self-assemble into ordered multimeric  
96 lattices. The resulting assemblies must be stable during virus formation and  
97 transmission to a new target cell, but also ready to disassemble in the newly infected  
98 cell, requiring structural flexibility of the protomers. Beyond protein-protein interactions  
99 involved in capsid assembly itself, capsid proteins generally undergo crucial  
100 interactions with other components of the virion, e.g., the viral genome. Finally, the  
101 capsid surface represents an essential contact interface between virus and host cell in  
102 the early phase of infection, mediating cell entry in the case of non-enveloped viruses,  
103 or interacting with critical host cell dependency or restriction factors in the case of  
104 enveloped viruses. Consequently, a large proportion of the surface exposed amino  
105 acids of a viral capsid protein is involved in intermolecular contacts that are crucial for  
106 virus replication, which renders these proteins highly susceptible to genetic  
107 modification. Fusion of a capsid protein to a relatively large genetic label, e.g., green

108 fluorescent protein (GFP) or other fluorescent proteins, is thus generally prone to  
109 severely affect virus infectivity.

110 These considerations also apply to HIV-1 CA. The protein is encoded as a subdomain  
111 of the structural polyprotein Gag, from which it is released by the viral protease (PR)  
112 concomitant with virus budding to allow for formation of the mature capsid. With a  
113 molecular mass of ~24 kDa, mature CA is of a similar size as GFP. Hexa- and  
114 pentamers of CA are the core structural elements of the immature Gag polyprotein  
115 shell forming the nascent virus bud in HIV-1 producing cells, as well as of the mature  
116 capsid lattice. CA pentamers, immature and mature hexamers employ different  
117 protein-protein interfaces; together, these interfaces involve most of the exposed  
118 surface of the CA monomer (Mattei et al. 2016; Zhao et al. 2013; Grime and Voth 2012;  
119 Ganser-Pornillos, Cheng, and Yeager 2007; Pornillos, Ganser-Pornillos, and Yeager  
120 2011). Accordingly, scanning mutagenesis analyses found HIV-1 CA to be highly  
121 genetically fragile (von Schwedler *et al.*, 2003; Fassati, 2012; Rihn *et al.*, 2013), with  
122 up to 89% of single amino acid exchanges tested abolishing or severely affecting virus  
123 replication (Rihn et al. 2013). It is thus not surprising that the introduction of genetically  
124 encoded labels - GFP or even a small peptide tag - at various positions within HIV-1  
125 CA have resulted in loss or severe reduction of infectivity (Pereira et al. 2011; Campbell  
126 et al. 2008; Ma et al. 2016; Burdick et al. 2020; Zurnic Bönisch et al. 2020).  
127 Complementation with wild-type (wt) virus, from at least equimolar amounts of wt CA  
128 to a substantial molar excess, was essential to restore infectivity (Campbell et al. 2008;  
129 Burdick et al. 2020; Zurnic Bönisch et al. 2020). While the use of wt complemented  
130 particles can be sufficient for fluorescent labeling, it is unclear whether the modified  
131 CA molecules are an integral part of the mature CA lattice; only ~ 50% of CA molecules  
132 present inside the virion are eventually used to form the mature capsid (J. A G Briggs  
133 et al. 2004; Lanman et al. 2004), and incorporated fusion proteins may be preferentially  
134 excluded from the mature lattice.

135 We therefore established and applied a minimal invasive labeling strategy for HIV-1  
136 CA based on genetic code expansion and click labeling. This method involves the  
137 exchange of a selected amino acid residue in the protein of interest with a non-  
138 canonical amino acid (ncAA) carrying a highly reactive bio-orthogonal functional group  
139 by a process termed amber suppression (Figure 1a); this residue is subsequently  
140 covalently coupled to a fluorophore functionalized with a cognate reaction partner  
141 (Figure 1a; Lang and Chin, 2014; Nikić and Lemke, 2015; Kelemen, Erickson and

142 Chatterjee, 2018; Müller, Sakin and Müller, 2019; Krauskopf and Lang, 2020; de la  
143 Torre and Chin, 2021). Using this approach, we generated a CA-labeled HIV-1  
144 derivative that largely retained infectivity; in contrast to previous approaches for direct  
145 CA labeling, our minimally modified derivative did not require complementation with wt  
146 virus. Direct labeling with a bright and photostable chemical dye allows the application  
147 of various imaging methods, i.e., live-cell imaging, super-resolution nanoscopy, or  
148 CLEM. The virus variant click labeled with a bright and photostable chemical dye thus  
149 enabled us to directly assess the amount of CA associated with entering subviral  
150 complexes outside and within the nucleus of infected HeLa-derived cells and primary  
151 CD4<sup>+</sup> T-cells, to visualize CA containing structures in the nucleus by nanoscopy and  
152 correlative microscopy and to study the effect of the CA-binding drug PF74 on the  
153 nuclear complexes.

154

## 155 **Results**

156

### 157 *Generation of an HIV-1 variant carrying a bio-orthogonal amino acid within CA*

158 To allow for minimally invasive labeling of HIV-1 CA by genetic code expansion (GCE;  
159 Figure 1a), we introduced an amber stop codon at a position of interest into the CA  
160 coding sequence within the *gag* open reading frame of the proviral plasmid pNLC4-3  
161 (Bohne and Kräusslich 2004). In order to avoid GCE modification of the viral protein R  
162 (Vpr), which is incorporated into the virion in high amounts (B. Müller et al. 2000), we  
163 first exchanged the amber stop codon of *vpr* to an opal codon (TGA), resulting in  
164 plasmid pNLC4-3\*. Albeit this mutation did not alter the coding sequence of viral  
165 proteins or virion infectivity, the corresponding virus was termed HIV-1\* to indicate this  
166 modification. Since neither the efficiency of amber suppression in a given sequence  
167 context in eukaryotic cells, nor the effect of ncAA incorporation on viral functionality  
168 can be predicted with certainty, we tested a panel of 19 amber mutations at sites  
169 located towards the outer surface of the capsid lattice for suppression efficiency and  
170 virus infectivity (Schifferdecker, Sakin et al., in preparation). Based on a comparison of  
171 Gag expression levels and viral infectivity upon ncAA incorporation, we selected a virus  
172 variant in which residue alanine 14 in CA was replaced by a non-canonical amino acid  
173 (HIV-1\*CA14<sup>ncAA</sup>) for further analyses.


174 For virus preparation, HEK293T cells were co-transfected with the respective mutant  
175 proviral plasmid and pNESPIyRS-eRF1dn-tRNA. The latter plasmid encodes for a  
176 complete amber suppression system, consisting of modified tRNA, a cognate  
177 genetically engineered pyrrolysine aminoacyl-tRNA synthetase (Nikić et al. 2016), and  
178 a dominant-negative version of the eukaryotic release factor eRF1 that improves  
179 amber suppression efficiency in eukaryotic cells (Schmied et al. 2014). To produce  
180 functionalized virus particles, cells were grown in the presence of the small ncAA  
181 cyclopropene lysine (CpK). While truncation of Gag at position 14 of CA would prevent  
182 virus formation, incorporation of CpK by amber suppression should result in the  
183 expression of full-length Gag and thereby promote HIV-1 particle assembly.  
184 Immunoblot analysis of cell lysates indeed demonstrated the presence of full-length  
185 Gag polyprotein precursor when HIV-1\*CA14<sup>TAG</sup> expressing cells were grown in the  
186 presence of CpK, whereas full-length Gag was not detected when CpK was omitted  
187 from the growth medium (Figure 1 – figure supplement 1). Thin-section electron  
188 microscopy (EM) revealed late budding sites and immature- as well as mature-like  
189 virions at the plasma membrane and in the vicinity of HIV-1\*CA14<sup>ncAA</sup> expressing cells,  
190 that were morphologically indistinguishable from typical HIV-1 wild-type (wt) budding  
191 sites and virions (Figure 1b). We concluded that Gag expression of HIV-1\*CA14<sup>TAG</sup> is  
192 ncAA dependent and the modified CA domain is competent for immature and mature  
193 lattice assembly.

194

#### 195 *Characterization of click labeled HIV-1 virions*

196 We next prepared virus particles from the supernatant of HIV-1\*CA14<sup>ncAA</sup> producing  
197 cells and subjected them to click labeling using the membrane-permeable dye silicon  
198 rhodamine tetrazine (SiR-Tet; (Lukinavičius et al., 2013)), generating HIV-1\*CA14<sup>SiR</sup>.  
199 As a control, HIV-1\* wt particles were prepared under amber suppression conditions  
200 and stained in parallel. Consistent with the detection of viral assembly sites and  
201 particles in electron micrographs (Figure 1b), virus was recovered from the tissue  
202 culture supernatant of HIV-1\*CA14<sup>ncAA</sup> expressing cells. Particle yields were somewhat  
203 reduced compared to the HIV-1\* wt control, in line with the fact that amber suppression  
204 is usually incomplete in eukaryotic cells (optimal ncAA incorporation efficiencies in the  
205 range of ~25-50 %; (Rodriguez, Lester, and Dougherty 2007; Schmied et al. 2014;  
206 Sakin et al. 2017)). On average, we obtained 5-10-fold lower yields for HIV-1\*CA14<sup>SiR</sup>

207 compared to HIV-1\* (Figure 1c, d). Consistent with the observation of morphologically  
208 mature particles by EM, click labeled particles displayed regular Gag and GagPol  
209 processing products (Figure 1e), with clear bands for mature RT heterodimer (p51,  
210 p66) and mature CA (p24). In-gel fluorescence revealed a distinct SiR labeled band  
211 corresponding to a mass of approximately 24 kDa for HIV-1\*CA14<sup>SiR</sup>, but not for HIV-  
212 1\* control particles (Figure 1f). Taken together, these findings indicate specific GCE-  
213 dependent labeling of CA *via* amber suppression at position 14 of HIV-1 CA.  
214



215

216 **Figure 1. Production and characterization of click labeled HIV-1 (HIV-1\*CA14<sup>SiR</sup>).**

217 **(a)** Experimental scheme for GCE and click-labeling. The system used here requires  
218 the introduction of an amber stop codon (UAG) at a specific site into the coding  
219 sequence of the protein of interest. A genetically engineered bio-orthogonal tRNA /  
220 aminoacyl-tRNA synthetase pair mediates incorporation of a non-canonical amino acid  
221 (ncAA) at the chosen position. In a second step, a highly reactive group of the ncAA is  
222 covalently linked to a fluorophore carrying a cognate reactive group (e.g., a tetrazine  
223 group reacting with a cyclopropane group at the ncAA *via* strain-promoted inverse



224 electron-demand Diels-Alder cycloaddition (SPIEDAC)). Image created with  
225 BioRender.com **(b)** Morphology of HIV-1\*CA14<sup>ncAA</sup> assembly sites and particles.  
226 HEK293T cells were co-transfected with pNLC4-3\*CA14<sup>TAG</sup> and pNESPIyRS-eRF1dn-  
227 tRNA and grown in the presence of 550  $\mu$ M CpK. At 44 h p.t., cells were fixed,  
228 embedded, and analyzed by thin-section EM as described in materials and methods.  
229 **(c,d)** Virus production. Click labeled particles were prepared from the supernatant of  
230 HEK293T cells co-transfected with either pNLC4-3\* or pNLC4-3\*CA14<sup>TAG</sup> and  
231 pNESPIyRS-eRF1dn-tRNA. Cells were grown in the presence of 500  $\mu$ M CpK as  
232 described in materials and methods. Particle yield in the final preparations was  
233 determined via quantitation of RT activity (SG-PERT assay;(Pizzato et al. 2009)) **(c)**  
234 and by determination of CA amounts using quantitative immunoblot as described in  
235 materials and methods **(d)**. The graphs show mean values and SD from four  
236 independent experiments. **(e)** Immunoblot analysis of virus preparations. Particle  
237 lysates were separated by SDS-PAGE, and proteins were transferred to nitrocellulose  
238 membranes by semi-dry blotting. Viral proteins were detected using polyclonal antisera  
239 raised against recombinant HIV-1 RT or CA. Bound antibodies were detected by  
240 quantitative immunofluorescence with a Li-COR CLx infrared scanner, using  
241 secondary antibodies and protocols according to the manufacturer's instructions. An  
242 asterisk indicates non-specific reactivity with bovine serum albumin carried over from  
243 the medium **(f)** In-gel fluorescence. Particle lysates prepared as in (e) were separated  
244 by SDS-PAGE, and the acrylamide gel was scanned using a Li-COR CLx infrared  
245 scanner set at an emission wavelength of 700 nm.

246


#### 247 *Fluorescence labeling and infectivity of click labeled virions*

248 To test specificity and efficiency of SiR staining, labeled particles adhered to a glass  
249 chamber slide were fixed, permeabilized, and immunostained with antiserum raised  
250 against HIV-1 CA to validate that detected signals corresponded to virus particles.  
251 Confocal micrographs were recorded in the channels corresponding to the CA  
252 immunofluorescence (IF) stain (green) and direct CA labeling with SiR (magenta)  
253 (Figure 2a). Regions of interest (ROIs) corresponding to the position of virus particles  
254 were defined based on CA(IF) signals. Measurement of SiR fluorescence intensities in  
255 these ROIs revealed weak background staining in the case of HIV-1\* (Figure 2a, left  
256 panel). In contrast, distinct SiR signals co-localizing with CA(IF) punctae were detected

257 for HIV-1\*CA14<sup>SiR</sup> (Figure 2a, right panel). Quantitative analyses of images from  
258 multiple independent experiments confirmed this visual impression (Figure 2b). Only  
259 ~8.5% of HIV-1\* particles were classified as SiR positive, with fluorescence intensities  
260 only slightly above the background level (~1,000 a.u.). In contrast, >95% HIV-  
261 1\*CA14<sup>SiR</sup> particles displayed clear SiR staining, with a mean fluorescence intensity of  
262 ~15,000 a.u. Variation in SiR fluorescence intensities between individual particles is  
263 expected, since particle size and CA content of HIV-1 virions varies, with ~1,700-3,100  
264 CA monomers estimated per particle (Carlson et al. 2008). Beyond that, the range of  
265 SiR signal intensities observed also indicates a range of click labeling efficiencies.  
266 Despite some variability in the preparation, the vast majority of HIV-1\*CA14<sup>CpK</sup> particles  
267 could be efficiently click labeled with SiR, attaining fluorescence intensities suitable for  
268 fluorescence microscopy of infected cells.

269 To test the effect of introducing a synthetic fluorophore at position 14 on CA  
270 functionality, the infectivity of click labeled particles was assessed by titration of labeled  
271 particles on TZM-bl cells, followed by immunostaining against the HIV-1 matrix protein  
272 (MA) to identify infected cells. As shown in Figures 2c and d, relative infectivity of HIV-  
273 1\*CA14<sup>SiR</sup> was only mildly reduced by an average of ~2-fold compared to HIV-1\*, a  
274 substantial improvement compared to previous genetic labeling strategies (Campbell  
275 et al. 2008; Burdick et al. 2020; Zurnic Bönisch et al. 2020; Pereira et al. 2011). Thus,  
276 minimal invasive labeling by GCE allows direct labeling of HIV-1 CA without requiring  
277 complementation with wt virus.

278



279

280

281 **Figure 2. Characterization of CA click labeled particles.** (a) Analysis of labeling  
282 efficiency. Particles harvested from the supernatant of virus producing HEK239T cells  
283 were subjected to click labeling. Particles were then immobilized on PEI coated  
284 chamber slides, fixed, and permeabilized. Particles were immunostained using  
285 antiserum raised against HIV-1 CA, and specimens were imaged by spinning disk  
286 confocal microscopy (SDCM). Scale bars 5  $\mu$ m. (b) Hexabin plots of detected particles.  
287 Mean intensities of CA(SiR) are plotted against mean intensity CA(IF) for HIV-1\* and  
288 HIV-1\*CA14<sup>SiR</sup>. The color intensity of the hexagons corresponds to the number of  
289 particles displaying the indicated intensity values. The graphs represent pooled data  
290 from 12 fields of view from three independent virus preparations. The red line indicates  
291 the threshold  $t=1,000$ . (c) Infectivity of click labeled particles. The indicated virus  
292 particles were prepared as in (a) and subjected to click labeling. Particle yield was  
293 assessed by RT activity assay (Pizzato et al. 2009), and samples were titrated on TZM-  
294 bl indicator cells seeded in 15-well ibidi  $\mu$ -angiogenesis slides. 50  $\mu$ M T-20 was added  
295 at 6 h p.i. to prevent second-round infection in the case of wt. Cells were fixed,  
296 permeabilized, and immunostained using a polyclonal rabbit antiserum raised against  
297 recombinant HIV-1 MA at 48 h p.i. Samples were imaged by SDCM. The percentage

298 of infected cells was determined using Fiji software. The graphs show mean values  
299 and SD from five independent infection experiments using five independent particle  
300 preparations (n=5,700-7,700 cells were counted per condition). Lines represent linear  
301 regression based on the mean values. **(d)** Relative infectivity of a virus preparation (%  
302 infected cells/mU RT) was determined as in (c), and the values obtained for HIV-  
303 1\*CA14<sup>SiR</sup> were normalized to the value obtained for HIV-1\* virus in the same  
304 experiment. All cells counted in (c) were used for quantification. The graph represents  
305 the mean value and SD from five independent experiments.

306

### 307 *Detection of click labeled HIV-1 in infected cells*


308 Having established a suitable labeling strategy, we used labeled particles to infect  
309 target cells. Initial experiments were performed in HeLa TZM-bl cells (Wei et al. 2002),  
310 a widely used model cell line in HIV-1 research. Cells infected with HIV-1\*CA14<sup>SiR</sup> at  
311 an MOI~0.8 were fixed at 18 h post infection (h p.i.). Immunostaining with antiserum  
312 against CA was performed under conditions that allow for immunodetection of cytosolic  
313 and nuclear complexes (T. G. Müller et al. 2021) to validate that detected SiR signals  
314 corresponded to HIV-1 particles. Labeled particles could be visualized by spinning disc  
315 confocal microscopy (SDCM) in the cellular environment (Figure 3 – figure supplement  
316 1). Confocal images revealed punctate SiR signals in the cytosol, close to the nuclear  
317 envelope and within the nucleus of infected cells. Co-localization with CA(IF) staining  
318 confirmed that these signals represented entering viral structures (Figure 3a and  
319 Figure 3 - figure supplement 2).

320 Next, TZM-bl cells infected with HIV-1\* or HIV-1\*CA14<sup>SiR</sup> were fixed and analyzed for  
321 the presence of click labeled subviral particles inside the nucleus at different time  
322 points after infection. Consistent with earlier results (Zurnic Bönisch et al. 2020; Burdick  
323 et al. 2020; T. G. Müller et al. 2021), we observed nuclear CA(IF) positive foci in HIV-  
324 1\* infected cells as early as 6 h post infection (Figure 3b, black), while such signals  
325 were absent in noninfected cells (Figure 3b, grey). Importantly, we detected SiR  
326 positive complexes in the nucleus of HIV-1\*CA14<sup>SiR</sup> infected cells, with the vast  
327 majority also positive for CA(IF) (Figure 3b, magenta). Nuclear entry appeared to be  
328 delayed for HIV-1\*CA14<sup>SiR</sup> compared to HIV-1\* by approximately 12 h. Nevertheless,  
329 comparable numbers of cells with detectable capsid-like objects in the nucleus and the  
330 number of objects per cell were reached between 12 and 18 h p.i. (Figure 3b and c).

331 At 12 h p.i., HIV-1\*CA14<sup>SiR</sup> reached the highest number of nuclear particles per cell,  
 332 with an average of  $4.58 \pm 4.12$ , similar to HIV-1\* with  $5.91 \pm 4.11$ .

333 Delayed detection of subviral complexes in the nucleus may be due to slower uptake,  
 334 slower trafficking towards the nuclear envelope, delayed passage through the NPC, or  
 335 a combination thereof. In order to distinguish between these possibilities, we extended  
 336 the time-resolved quantification to objects in close vicinity to the nuclear envelope  
 337 (Figure 3d). This analysis revealed that the HIV-1\*CA14<sup>SiR</sup> derived subviral structures  
 338 reached the nuclear envelope with similar kinetics to HIV-1\* particles (Figure 3d, NE  
 339 assoc.). A comparable average proportion of CA containing objects was detected at  
 340 the nuclear envelope in both cases at 6 h, while the numbers of nuclear capsids were  
 341 lower for HIV-1\*CA14<sup>SiR</sup> at that time (Figure 3d, Nucleus). In contrast, the highest  
 342 proportion of HIV-1\*CA14<sup>SiR</sup> nuclear objects with  $4.20 \pm 1.80\%$  was detected at 18 h  
 343 p.i., while HIV-1\* reached similar levels already at 6 h p.i. We conclude that uptake and  
 344 intracellular trafficking of HIV-1\*CA14<sup>SiR</sup> complexes occurs with similar efficiency as for  
 345 the wt virus, but transport into the nucleus is slower, offering a possible explanation for  
 346 the slightly reduced infectivity of HIV-1\*CA14<sup>SiR</sup> virions. This implies that the  
 347 mechanistic action of the capsid in nuclear import underlies tight margins with respect  
 348 to its biophysical properties.

349



352 **Figure 3. Detection of CA in the nucleus of infected HeLa-derived cells.** TZM-bl  
353 cells were infected with HIV-1\* or HIV-1\* CA14<sup>SiR</sup> particles (~MOI 0.8), treated with 15  
354  $\mu$ M PF74 for 1 h, fixed at 6, 9, 12 and 18 h p.i. and imaged by SDCM. **(a)** Single z slice  
355 of a representative cell infected with HIV-1\* CA14<sup>SiR</sup> at 18 h p.i. and one enlarged z slice  
356 are shown. Scale bars: 10  $\mu$ m (cell) and 1  $\mu$ m (enlargement). Mean filter and  
357 background subtraction was applied for clarity. The image shows a representative  
358 image from one of three independent experiments. See Figure 3-figure supplement 1  
359 and 2 for additional data. **(b-d)** Infection time course of click labeled HIV-1\* CA14<sup>SiR</sup>  
360 compared to HIV-1\*. **(b)** Quantification of cells positive for nuclear CA positive objects  
361 over time post infection for HIV-1\* (black; CA(IF)), HIV-1\* CA14<sup>SiR</sup> (red; CA(IF)/CA(SiR))  
362 and noninfected control (grey; CA(IF)). Mean values and SD from three independent  
363 experiments are shown (n>115 cells per timepoint). **(c)** Number of nuclear CA foci per  
364 cell determined for cells infected with HIV-1\* (black) or HIV-1\* CA14<sup>SiR</sup> (red) at the  
365 indicated timepoints. n>120 cells were analyzed per sample. The median and quartile  
366 lines are indicated in grey. **(d)** Localization of particles within a cell for HIV-1\* (dark  
367 grey) and HIV-1\* CA14<sup>SiR</sup> (light grey). The proportion of total particles per cell detected  
368 at the PM or in the cytoplasm (= PM/cytoplasm) at the nuclear envelope (=NE  
369 associated) or inside the nucleus was determined at the indicated time points. Data  
370 from two of three independent experiments are shown. n>20 cells were analyzed per  
371 time point, and error bars represent the SD of the mean.


372

### 373 *Characterization of nuclear CA<sup>SiR</sup> containing complexes*

374 A long-standing question in the field of HIV-1 early replication is the question of when  
375 and where capsid uncoating takes place. The possibility to directly detect CA  
376 molecules clicked to a synthetic fluorophore enabled us to assess the amounts of CA  
377 associated with subviral complexes at different intracellular sites, without the influence  
378 of differential epitope accessibility or of a tag domain that potentially confers different  
379 properties to a subpopulation of CA molecules. Nevertheless, comparing labeling  
380 intensities for nuclear, cytoplasmic, and extracellular particle-associated structures  
381 may be confounded in diffraction-limited microscopy by the failure to resolve closely  
382 adjacent individual capsids. Clusters of nuclear capsids had indeed been observed by  
383 CLEM analyses in our previous study (T. G. Müller et al. 2021).

384 To determine whether nuclear cluster formation occurred under our conditions, we  
385 exploited the fact that the chemical dye conjugated to the capsid surface renders the  
386 modified virus suitable for super-resolution microscopy. With a lateral resolution of <50  
387 nm, STED nanoscopy allows visual separation of closely adjacent CA objects. TZM-bl  
388 cells were infected with HIV-1\*CA14<sup>SiR</sup> at two different MOIs. An MOI of ~0.8  
389 corresponded to the conditions generally used in our experiments; a 10-fold higher  
390 virus dose (MOI ~8) was applied in a parallel experiment to potentially enhance capsid  
391 clustering. At 18 h p.i., cells were fixed, immunostained against CA, and imaged using  
392 a STED system in confocal and STED mode (Figure 4). Nuclear CA(IF)/(SiR) double-  
393 positive objects were detected under both conditions (Figure 4a, arrowheads). While  
394 these objects appeared as individual punctae in diffraction-limited micrographs from  
395 the IF and SiR channels at both MOIs (Figure 4b, top and middle row), imaging of the  
396 SiR channel in STED mode revealed differences between individual punctae. Some  
397 diffraction-limited punctae in the nucleus represented individual capsid-like objects  
398 when imaged by STED (Figure 4b, left panel, bottom row). In contrast, other punctae  
399 were resolved into small clusters of 2-4 closely apposed CA-containing objects by  
400 super-resolution microscopy (Figure 4b, right, bottom panel), consistent with  
401 observations made by electron tomography (T. G. Müller et al. 2021; Zila et al. 2021).  
402 A quantitative analysis of cluster sizes (Figure 4c) revealed that the propensity for  
403 capsid clustering in the nucleus correlated with the amount of virus used for infection:  
404 at an MOI~0.8, the vast majority of punctae (~88%) corresponded to individual capsid-  
405 like objects in the nucleus, and clusters of more than two objects were not observed.  
406 On the other hand, almost half of the nuclear punctae (~43%) corresponded to clusters  
407 of 2-4 objects when cells were infected with the high MOI~8. We conclude that nuclear  
408 capsid clustering is rarely observed at the MOI of 0.8 used throughout this study. The  
409 previously observed capsid clustering in distinct nuclear positions appears to occur  
410 preferentially at high MOI.

411



412

413 **Figure 4. Dose-dependent clustering of nuclear capsids in HeLa-derived cells.**


414 TZM-bl cells were infected with HIV-1\* CA14<sup>SiR</sup> at the indicated MOI for 18 h, treated  
415 with 15  $\mu$ M PF74 for 1 h, immunostained against CA (green) and lamin A (blue) and  
416 imaged using an Abberior STED setup. Mean filter and background subtraction was  
417 applied to all images for clarity. **(a)** Micrographs of TZM-bl cells infected with an MOI  
418  $\sim$ 0.8 (left) or MOI  $\sim$ 8 (right). Arrowheads indicate nuclear CA(IF)/CA(SiR) positive  
419 objects shown enlarged in (b). Scale bars: 10  $\mu$ m. **(b)** Representative images of  
420 nuclear CA containing objects from cells infected with a low MOI (MOI $\sim$ 0.8, left panel)  
421 or a high MOI (MOI $\sim$ 8, right panel). CA(IF) and CA(SiR) were imaged in confocal mode  
422 (top and middle row, respectively). CA(SiR) images were also recorded in STED mode  
423 (bottom row). The figure shows four representative foci each from one of two individual  
424 experiments. Mean filter and background subtraction were applied. Scale bars: 500  
425 nm. **(c)** Diffraction-limited nuclear foci were analyzed by STED nanoscopy in cells  
426 infected with an MOI $\sim$ 0.8 (n = 33) and an MOI $\sim$ 8 (n = 44) and classified by the number  
427 of individual capsids per focus.

428



429 We next proceeded to SiR fluorescence intensity measurements, comparing the signal  
430 intensity of extranuclear HIV-1 particles to that of subviral structures in the nucleus.  
431 Staining of the plasma membrane with mCling before infection revealed that under our  
432 conditions most cell-associated particles in the cytosolic region represented virions  
433 present in endosomes, corresponding to a pre-fusion state of the virus (Figure 5 –  
434 figure supplement 1). To ensure that these extranuclear punctae represented single  
435 objects, cytoplasmic foci were analyzed in STED mode. We found that ~95% (n=79)  
436 of analyzed objects corresponded to an individual object, while only ~5% (n=4) of  
437 these foci were resolved into two objects by nanoscopy (Figure 5 – figure supplement  
438 2). As illustrated by the cartoon in Figure 5a, complete virions comprise on average  
439 ~2,400 CA molecules, while only ~1,200-1,500 of these are part of the mature fullerene  
440 capsid (John A.G. Briggs et al. 2003; Carlson et al. 2008; Lanman et al. 2004) that  
441 represents a post-fusion state. Assuming equal click labeling efficiency of CA14<sup>ncAA</sup> for  
442 molecules that are part of the mature lattice and those that remain free in the viral  
443 volume, the average SiR intensity of complete capsids would be expected to  
444 correspond to ~60% of the average intensity of complete virions from the same  
445 preparation. We infected TZM-bl cells at an MOI of 0.8 and quantified the SiR intensity  
446 of >6,000 virions attached to the cell or in the cytosolic region and of >100 nuclear  
447 punctae. The average SiR intensity of cell-associated and (mostly) endosomal particles  
448 in the cytosolic region exhibited an average of 17,649 a.u.. In contrast, the SiR intensity  
449 of nuclear subviral structures averaged 9,835 a.u. (Figure 5b), i.e., ~56% of the  
450 average intensity of complete virions, in line with the predicted relative CA content of  
451 the mature capsid. Based on these findings, we conclude that the CA(SiR) containing  
452 objects in the nuclei of these cells correspond approximately to a full complement of  
453 the mature capsid.

454



455

456 **Figure 5. Largely intact capsids are detected in the nucleus of HeLa-derived**  
457 **cells.** TZM-bl cells were infected with HIV-1\* or HIV-1\*CA14<sup>SiR</sup> (MOI~0.8), treated with  
458 15  $\mu$ M PF74 for 1 h before fixation at the indicated time points and imaged by SDCM.  
459 **(a)** Scheme of the relative CA content in complete virions (~ 2,400 CA) on glass/plasma  
460 membrane or in endosomes in the cytosol. Post-fusion capsids contain only the CA  
461 molecules incorporated into the mature capsid lattice (~ 1,500 CA). Image created with  
462 BioRender **(b)** Quantification of CA(SiR) intensities associated with CA(IF) positive  
463 objects at the indicated localizations. Data from three independent experiments are  
464 shown. Cells from seven fields of view were analyzed ( $n_{\text{particles}}= 6441$  PM/cytoplasm,  
465 135 nucleus). Lines indicate median values (PM/cytoplasm:  $17,649.22 \pm 11,663.47$ ;  
466 nucleus:  $9,835.08 \pm 5,708.14$ ) and interquartile range. Significance was determined by  
467 two-tailed Student's t-test (\*\*\*)  $< 0.001$ ). **(c)** Quantification of CA(SiR) intensities of  
468 nuclear objects. TZM-bl cells were treated with DMSO or 15  $\mu$ M PF74 for 1 h prior  
469 fixation at 17 h p.i.. Lines indicate median values (DMSO:  $2,086.83 \pm 456.35$ ,  $n=100$ ;  
470 PF74: =  $2,164.51 \pm 783.45$ ,  $n=100$ ) and interquartile range. Significance was  
471 determined by two-tailed Student's t-test (n.s.  $>0.05$ ).

472 The small molecule inhibitor PF74 (Blair et al. 2010) binds to the HIV-1 capsid in a  
473 pocket overlapping the binding sites for the FG motifs of various nucleoporins and for  
474 the nuclear host protein CPSF6; the compound inhibits HIV-1 replication by multiple  
475 mechanisms (McArthur et al. 2019; Novikova et al. 2019; Thenin-Houssier and Valente  
476 2016). Treatment with high concentrations of PF74 has been reported to destabilize  
477 the capsid (Shi et al. 2011; Price et al. 2014; Blair et al. 2010; Pornillos et al. 2010; Lee  
478 et al. 2012; Yang Yang, Luban, and Diaz-Griffero 2014), but data that we had obtained  
479 using CA(IF) detection argued against a PF74 induced loss of CA from nuclear  
480 complexes (T. G. Müller et al. 2021). Since we cannot exclude that results obtained by  
481 immunodetection are influenced by differential CA epitope exposure, we re-addressed  
482 this issue employing direct CA labeling. TZM-bl cells were infected with HIV-1\*CA14<sup>SiR</sup>  
483 particles for 17 h and treated with 15  $\mu$ M PF74 or DMSO for 1 h, followed by fixation,  
484 permeabilization, methanol extraction, and SDCM imaging. As shown in Figure 5c,  
485 CPSF6 was removed from the subviral complexes, in accordance with earlier results  
486 (T. G. Müller et al. 2021). In contrast, mean CA(SiR) intensity remained unaltered,  
487 indicating that the capsid remains largely stable under these conditions.

488


489 *Detection of directly labeled HIV-1 capsids in primary cells*

490 To validate our results in a physiologically relevant cell type, primary human CD4<sup>+</sup> T  
491 cells from healthy blood donors were infected, subjected to IF staining against CA, and  
492 imaged by SDCM at 24 h p.i. (Figure 6a and Figure 6 – figure supplement 1). We  
493 readily detected nuclear subviral SiR positive structures in HIV-1\*CA14<sup>SiR</sup> infected  
494 cells, indicating that nuclear replication complexes retained CA also in these primary  
495 cells (Figure 6a). Consistent with prior observations made in this cell type (Zila et al.  
496 2019), the majority of SiR-positive objects were not associated with CA(IF) signals  
497 (9/11 particles; Figure 6a, left) when fixation and immunostaining were performed  
498 under standard conditions. As outlined above, treatment with 15  $\mu$ M PF74 for 1 h  
499 dissociates the large clusters of CPSF6 from nuclear subviral complexes. We observed  
500 that this in turn renders nuclear CA accessible for IF detection in T cells, presumably  
501 by exposure of CA epitopes upon CPSF6 displacement (T. G. Müller et al. 2021).  
502 Accordingly, brief PF74 treatment allowed for detection of CA(IF) signals co-localizing  
503 with nuclear CA(SiR) punctae (13/16; Figure 6a, right). We conclude that the direct CA  
504 labeling strategy presented here overcomes technical artifacts that hamper IF  
505 analyses.

506 Further quantitative analyses using primary CD4<sup>+</sup> T cells prepared from six blood  
507 donors revealed similar numbers of nuclear capsid structures in cells infected with HIV-  
508 1\*CA14<sup>SiR</sup> than in cells infected with HIV-1\* at 24 h p.i. (Figure 6b). SiR intensity  
509 measurements were only performed for intranuclear objects in this case since high  
510 background due to SiR accumulation in the narrow cytoplasm of T cells precluded  
511 reliable analysis of individual particles in the extranuclear region (see Figure 6a and  
512 Figure 6 – figure supplement 1). Quantitation of SiR intensities of nuclear punctae in  
513 cells infected with an MOI~0.8 yielded similar average intensities as measured in TZM-  
514 bl cells (mean=12,485 a.u.), indicating the presence of a complete or nearly complete  
515 mature capsid in the nuclear complexes in primary T cells (Figure 6c). Cells infected  
516 with an MOI of ~8 displayed higher CA(SiR) intensities of diffraction-limited nuclear  
517 objects (mean=39,502 a.u.), suggesting intranuclear clustering of capsids, as  
518 observed in TZM-bl cells (Figure 4).

519 Our findings from CA(SiR) intensity measurements argue for the presence of a full  
520 capsid complement at subviral structures in the nucleus. These data strengthen  
521 conclusions from several recent studies suggesting that the mature capsid lattice may  
522 be completely or largely intact on nuclear subviral objects (T. G. Müller et al. 2021;  
523 Burdick et al. 2020; Selyutina et al. 2020). However, fluorescence signals do not yield

524 information on the architecture of nuclear CA14<sup>SiR</sup> containing objects. Therefore, we  
525 complemented our analyses by performing CLEM of infected SupT1 T cells. In order  
526 to maximize the number of nuclear objects, infection was synchronized by the  
527 attachment of particles to the cells for 3 h at a low temperature (16°C) to prevent  
528 particle uptake by membrane fusion or endocytosis (Weigel and Oka, 1981; Melikyan  
529 *et al.*, 2000). Virus entry was then initiated by temperature shift to 37°C (Zila *et al.*  
530 2019). At 24 h post temperature shift, specimens were prepared by high-pressure  
531 freezing (HPF) and freeze substitution, and 250 nm thick resin sections were subjected  
532 to SDCM in order to localize CA(SiR) containing structures, followed by correlative  
533 electron tomography (CLEM-ET) analysis. CA(SiR) positive objects could be identified  
534 by SDCM in the sections (Figure 6d), demonstrating that the brightness of signals  
535 derived from direct CA(SiR) labeling is sufficient for CLEM detection of cytosolic and  
536 nuclear (sub)viral structures. ROIs were defined based on the SiR signals and  
537 subjected to correlative ET analysis. Figure 6e shows an exemplary tomogram  
538 obtained from a ROI located within the nucleus. It reveals several closely attached  
539 electron-dense structures at the position of the SiR label, whose shape and dimension  
540 match those of intact or largely intact mature HIV-1 capsids (Figure 6f and  
541 supplementary movie 1). Such structures were recently identified in nuclei of infected  
542 cells by CLEM using fluorescently labeled HIV-1 IN as an indirect marker for subviral  
543 structures (Zila *et al.* 2021; T. G. Müller *et al.* 2021) and were interpreted as capsid  
544 shells based on their morphology. Here we demonstrate that such structures co-  
545 localize with nuclear foci comprising a high number of click labeled CA molecules,  
546 thereby providing direct evidence that the cone-shaped objects are HIV-1 capsids that  
547 have entered the nucleus of infected cells.



548

549 **Figure 6 Largely complete click labeled capsid structures detected in the**  
 550 **nucleus of primary CD4<sup>+</sup> T cells and T cell line. (a)** Activated CD4<sup>+</sup> T cells were  
 551 infected with HIV-1\*CA14<sup>SiR</sup> (MOI~0.8) for 24 h before DMSO/PF74 treatment for 1 h,  
 552 fixation, and methanol extraction. Samples were immunostained against CA (green)  
 553 and laminA (blue). Images show a single z slice through the cell. Enlargements show  
 554 the particle marked by the arrowhead. Scale bars: 10  $\mu$ m (overview) and 1  $\mu$ m  
 555 (enlargement). **(b)** Data analyzed from the experiment outlined in (a). The graph shows  
 556 the number of CA positive foci per nucleus in cells infected with HIV-1\* (n=35 cells,  
 557 mean=0.85) or HIV-1\*CA14<sup>SiR</sup> (n= 73 cells, mean=0.51). Pooled data from 6 different  
 558 blood donors are shown. Grey lines show median and interquartile lines. **(c)** CA(SiR)  
 559 intensities of nuclear objects in infected and activated CD4<sup>+</sup> T cells at an MOI~0.8  
 560 (n=13; mean=12,485  $\pm$  7,445 a.u.) and an MOI ~8 (n=7; mean=39,502  $\pm$  18,025 a.u.).  
 561 MOI was determined in TZM-bl cells. Grey lines show median and interquartile lines.  
 562 **(d-f)** Nuclear cone-shaped capsids detected by CLEM-ET. SupT1 cells were treated

563 with 1  $\mu$ M aphidicolin (APC) for 16 h to prevent cell division, before infection with HIV-  
564 1\*CA14<sup>SiR</sup> virions (2.3  $\mu$ U RT/cell, corresponds to an MOI~0.4 determined in TZM-bl  
565 cells). At 24 h p.i., cells were cryo-immobilized by high-pressure freezing, freeze  
566 substituted, and further processed for CLEM and ET as described in materials and  
567 methods. **(d)** SDCM image of a 250-nm thick resin section of the cell infected with HIV-  
568 1\*CA14<sup>SiR</sup> virions (magenta), post-stained with Hoechst (blue) and decorated with  
569 multi-fluorescent fiducials (Fd) for correlation. The arrowhead in the enlargement of the  
570 boxed region indicates a CA(SiR) signal within the Hoechst-stained nuclear region.  
571 Scale bars: 1  $\mu$ m (overview) and 200 nm (enlargement). **(e)** Computational slices  
572 through tomographic reconstructions at the correlated region boxed in (d) with views  
573 highlighting the presence of clustered capsid-reminiscent structures (black  
574 arrowheads) in the nuclear region. Nu, nucleus; NPC, nuclear pore complex; NE,  
575 nuclear envelope. Scale bar: 100 nm. **(f)** Segmented and isosurface rendered structure  
576 of the cones detected in (e). Magenta: capsid, yellow: NE, cyan: NPC. See also  
577 supplementary movie 1.

578

## 579 Discussion

580 Here we present a direct labeling approach for the HIV-1 CA protein that yields  
581 infectious and morphologically mature viral particles. The minimally invasive GCE /  
582 click labeling approach used here represents an ideal strategy for the versatile labeling  
583 of genetically fragile viral capsid proteins. Its potential for virus imaging has not been  
584 exploited, however, presumably because this method is still challenging in eukaryotic  
585 cells. While GCE has been explored in virology for the generation of conditionally  
586 replication-competent live attenuated vaccines (Yuan et al. 2017; Si et al. 2020; Wang  
587 et al. 2014), the combination of GCE and click labeling for the purpose of capsid  
588 imaging has only been successfully applied for the non-enveloped adeno-associated  
589 virus (AAV) (Zhang et al. 2018; Seo et al. 2020; Katrekar et al. 2018; Rubino et al.  
590 2012). Unlike HIV-1 CA, the AAV capsid protein has also been shown to tolerate  
591 modifications by peptide insertions (Asokan, Schaffer, and Samulski 2012; Kotterman  
592 and Schaffer 2014; Thadani et al. 2018; Börner et al. 2020; Grimm and Zolotukhin  
593 2015). Here, we demonstrate that GCE in conjunction with click labeling can also be  
594 applied to an enveloped virus with a highly multifunctional and extremely genetically  
595 fragile capsid protein. In contrast to other genetic tagging strategies described, the

596 minimally invasive approach allows labeling of HIV-1 CA without requiring  
597 complementation with wt virus.

598 The detection of a chemical fluorophore covalently attached to CA is independent of  
599 cellular context, sample treatment, or exposure of CA epitopes. Thereby, the approach  
600 overcomes limitations of IF detection that had previously led to different conclusions  
601 regarding the presence of HIV-1 CA at nuclear subviral complexes. CA amounts  
602 roughly corresponding to a full complement of a mature capsid were found to be  
603 associated with subviral complexes in the nuclei of a HeLa-derived cell line and primary  
604 human CD4<sup>+</sup> T cells, also upon inhibition of cell division by aphidicolin treatment. These  
605 findings support recent reports from us and others, which indicated that the nuclear  
606 pore channel is wider than assumed earlier, allowing HIV-1 capsids to pass the intact  
607 NPC, and that uncoating occurs after nuclear import (T. G. Müller et al. 2021; Zila et  
608 al. 2021; Selyutina et al. 2020; Dharan et al. 2020; Francis, Marin, Singh, et al. 2020;  
609 Burdick et al. 2020; Chen et al. 2016).

610 The HIV-1 capsid is the largest structure reported to pass through a nuclear pore to  
611 date, and cryo-ET reconstructions of NPCs in situ indicate that the NPC opening has  
612 a similar diameter to the broad end of the capsid (Zila et al. 2021). The HIV-1 capsid  
613 might thus represent the upper limit of NPC cargo size, so the addition of substantial  
614 molecular mass to its surface may block nuclear import. Our data show the site-specific  
615 introduction of a small molecule (molecular mass of SiR: 614.8 Da) into CA, at a  
616 position distant from the FG-binding pocket involved in interaction with nucleoporins  
617 and CPSF6, is tolerated by HIV-1. However, we did observe a delay in nuclear import  
618 that might be due to the additional mass and/or altered surface properties of the  
619 modified capsid. This will be a topic of further study.

620 Due to the use of synthetic dye molecules, the labeling strategy presented is  
621 compatible with a wide range of fluorescence imaging approaches, including live-cell  
622 microscopy, correlative imaging and super-resolution fluorescence microscopy  
623 techniques (i.e., STED (Klar and Hell 1999), dSTORM (Heilemann et al. 2008), and  
624 Minflux (Balzarotti et al. 2017)). By applying correlative imaging, we could provide  
625 direct evidence that capsid-shaped objects, as recently detected in the nucleus by  
626 correlative ET before as well as after separation of the viral genome from the bulk of  
627 viral proteins (T. G. Müller et al. 2021; Zila et al. 2021), indeed represent HIV-1 capsids  
628 or capsid-like remnants. Our observations are in apparent contrast to findings from

629 other recent fluorescence imaging-based studies that reported uncoating directly  
630 before or during passage of the capsid through the NPC (Mamede et al. 2017; Burdick  
631 et al. 2017; Francis et al. 2016; Francis and Melikyan 2018; Fernandez et al. 2019;  
632 Rasaiyaah et al. 2013; Arhel et al. 2007; Hulme, Perez, and Hope 2011; Zurnic Bönisch  
633 et al. 2020; Lukic et al. 2014; Y. Yang, Fricke, and Diaz-Griffero 2013), or a very rapid  
634 loss of the CA signal following nuclear uncoating (Burdick et al. 2020). These apparent  
635 discrepancies might be explained by different capsid labeling strategies. Loss of the  
636 capsid signal at the nuclear pore was observed when a tagged variant of the CA  
637 binding protein CypA was used as an indirect capsid marker (Francis et al. 2016;  
638 Francis and Melikyan 2018). It is conceivable that the marker protein could be  
639 displaced by Nup358, which also binds to the CypA binding loop in CA (Schaller et al.  
640 2011), at the outer ring of the nuclear pore. Rapid nuclear dissociation of the CA signal  
641 was observed upon incorporating a small proportion of eGFP-tagged CA as a capsid  
642 marker (Zurnic Bönisch et al. 2020; Burdick et al. 2020). In this case, CA molecules  
643 modified by a relatively large tag might alter the stability of the capsid or dissociate  
644 more rapidly from the viral structure than the native protein. We believe that the data  
645 obtained by correlative microscopy taken together argue that HIV-1 uncoating is not  
646 accompanied by rapid capsid disassembly, but rather occurs via separation of the viral  
647 genome from a broken capsid remnant (T. G. Müller et al. 2021). Combining the direct  
648 CA labeling described here with the recently developed fluorescence detection of the  
649 reverse transcribed genome (Blanco-Rodriguez et al. 2020; T. G. Müller et al. 2021)  
650 will provide us with the possibility to study the uncoating process in more detail using  
651 a combination of confocal imaging, nanoscopy, and correlative imaging.

652 STED nanoscopy allowed us to perform a more detailed analysis of the punctuate  
653 CA(SiR) signals within the cell by differentiating between individual CA foci and clusters  
654 of closely adjacent capsid-like objects. The vast majority (>95%) of individual CA<sup>SiR</sup>  
655 punctae detected in the cytosolic area of HeLa-derived model cells represented virions  
656 in endosomes, as determined by co-staining with a fluorescent membrane marker. This  
657 observation is consistent with efficient Env and receptor-independent endocytic uptake  
658 of HIV-1 into HeLa cells due to a high density of heparan sulfate at the plasma  
659 membrane (Marsh and Helenius 2006; Permanyer, Ballana, and Esté 2010; Gregory  
660 B. Melikyan 2014). In the nucleus, we observed small clusters of capsid-like objects  
661 upon high MOI infection, as we and others have recently described (Francis, Marin,  
662 Singh, et al. 2020; T. G. Müller et al. 2021; Rensen et al. 2021). Our analyses revealed



663 that this clustering is dependent on the amount of virus used for infection. Most nuclear  
664 signals represented single capsids at a lower MOI, whereas frequent clustering was  
665 observed at high MOI. These findings suggest that capsids enter the nucleus  
666 individually, but traffic via a limited number of routes to accumulate at defined sites of  
667 uncoating. This raises the question of whether HIV-1 uses a 'specialized' subset of  
668 nuclear pores for nuclear entry; the answer would not only be of interest in the context  
669 of HIV-1 replication, but also with respect to an understanding of the nuclear import  
670 process. Nup levels and presumably NPC composition have been found to influence  
671 HIV-1 replication (Kane et al. 2018), but the compositional and structural variability of  
672 NPCs between different cell types, or within an individual cell, is incompletely  
673 understood (reviewed in Knockenhauer and Schwartz, 2016). Nuclear speckles were  
674 recently identified as HIV-1 uncoating sites, with trafficking to these sites presumably  
675 guided by CPSF6 (Selyutina et al. 2020; Francis, Marin, Singh, et al. 2020; Rensen et  
676 al. 2021). Whether nuclear capsid clustering occurs in the context of natural infection  
677 - and whether it offers an advantage for virus replication or is simply a byproduct of the  
678 HIV-1 nuclear trafficking/uncoating pathway - is unknown. However, high MOI  
679 conditions can physiologically be reached by cell-to-cell infection (Sattentau 2010).  
680 Hence, the clustering phenotype warrants further investigation.

681 The direct labeling approach also allowed us to investigate the effect of the capsid  
682 inhibitor PF74, whose detailed mode of action and inhibition is still under investigation,  
683 on nuclear capsids. While some studies reported an accelerated uncoating with high  
684 PF74 concentrations (Blair et al. 2010; Lee et al. 2012; Yang Yang, Luban, and Diaz-  
685 Griffero 2014; Pornillos et al. 2010; Shi et al. 2011), others did not observe any  
686 dramatic change in capsid core stability (Rankovic et al. 2018; Rasaiyaah et al. 2013;  
687 T. G. Müller et al. 2021). Our data indicate that the displacement of CPSF6 from  
688 nuclear capsids by a high concentration of PF74 is not accompanied by capsid  
689 disassembly, consistent with *in vitro* findings that indicate breakage of lattice integrity  
690 by PF74, but stabilization of the remaining lattice (Márquez et al. 2018).

691 In conclusion, direct click labeling of HIV-1 CA is a versatile approach that significantly  
692 expands the possibilities to study the early events in HIV-1 replication with high  
693 temporal and/or spatial resolution using advanced fluorescence microscopy methods.  
694 Application for the HIV-1 CA provided direct proof that the capsid stays largely intact  
695 upon passage of the subviral complex into the nucleus and directly identified nuclear  
696 capsid-like structures that morphologically resembled the virion capsid by CLEM-ET.

697 The fact that the combination of GCE and click chemistry could successfully be applied  
 698 to a notoriously genetically fragile capsid protein of an enveloped virus opens the  
 699 perspective that this strategy may also advance and expand fluorescence labeling of  
 700 a broad range of other viruses.

701  
 702 **Acknowledgements**  
 703 We acknowledge microscopy support from the Infectious Diseases Imaging Platform  
 704 (IDIP) at the Center for Integrative Infectious Disease Research, Heidelberg. We thank  
 705 Eyal Arbely (The National Institute for Biotechnology in the Negev, Beer-Sheva, Israel)  
 706 for providing pEA168. pNESplyRS-eRF1dn-tRNA was kindly provided by Anna-Lena  
 707 Schäfer (University Hospital Heidelberg, Heidelberg, Germany).

708 This work was funded by the Deutsche Forschungsgemeinschaft (DFG; German  
 709 Research Foundation), Projektnummer 240245660, SFB 1129 project 6 (B.M.) and  
 710 project 5 (H.G.K.).

711  
 712 **Materials and Methods**

Reagent type (species) or resource	Designation	Source or reference	Identifiers	Additional information
Antibody	Rabbit polyclonal anti-HIV-1 CA	In-house	N/A	1:1000 IF
Antibody	Mouse monoclonal anti-Lamin A/C	Santa Cruz Biotechnology	RRID:AB_627875; Cat# sc-7292	1:100 IF; works for HeLa cells and MDM
Antibody	Mouse monoclonal anti-LaminB1	Santa Cruz Biotechnology	Cat# sc-365962	1:200 IF; works for SupT1 and primary CD4 <sup>+</sup> T cells
Antibody	Sheep polyclonal anti-HIV-1 CA	(Müller et al., 2009)	N/A	1:5000
Antibody	Rabbit polyclonal anti-HIV-1 RT	(Müller et al., 2004)	N/A	1:1000
Antibody	Rabbit polyclonal anti-HIV-1 MA	In-house	N/A	1:100?
Antibody	Alexa Fluor (405, 488, 568 and 647) secondary antibodies	Thermo Fisher Scientific	N/A	1:1000 IF
Antibody	sheep IgG, IRDye 680RD conjugated	LI-COR Biosciences	RRID:AB_1095444 2	1:10000
Antibody	rabbit IgG, IRDye 800CW conjugated	LI-COR Biosciences	RRID:AB_621848	1:10000
Antibody	Goat anti-mouse IgG conjugated with STAR ORANGE	Abberior GmbH	RRID:AB_2847853	1:200 STED
Cell line ( <i>H. sapiens</i> )	Hela TZM-bl	(Wei et al. 2002)	RRID:CVCL_B478	N/A
Cell line ( <i>H. sapiens</i> )	Embryonic kidney 293 T cells (HEK293T)	(Pear et al. 1993)	RRID:CVCL_0063	N/A
Cell line ( <i>H. sapiens</i> )	Human CD4 <sup>+</sup> T lymphoblast cells SupT1	(Smith et al. 1984)	RRID:CVCL_1714	N/A
plasmid	HIV-1 <sub>NL4-3</sub>	(Bohne and Kräusslich 2004)	N/A	HIV-1 proviral plasmid
plasmid	eRF1-E55D	(Schmied et al. 2014)	N/A	Dominant version of eRF1

plasmid	pEA168	(Cohen and Arbely 2016)	N/A	N/A
plasmid	tRNA <sup>Pyl</sup> /NESPylRS <sup>AF</sup>	(Nikić et al. 2016)	N/A	Modified pyrrolysine tRNA synthetase
plasmid	pNESPylRS-eRF1dn-tRNA	Schifferdecker, Sakin et al. in preparation	N/A	Amber suppression components
plasmid	HIV-1*	This study	N/A	pNLC4-3*
plasmid	HIV-1*CA14 <sup>TAG</sup>	This study	N/A	pNLC4-3*CA <sup>TAG</sup>
plasmid	pcDNA3.1 <sup>(+)</sup>	Thermo Fisher Scientific	Cat#V79020	Mammalian expression vector
Chemical	Paraformaldehyde (PFA)	Electron Microscopy Sciences	Cat#15700	16% aqueous solution
Chemical	SiR-tetrazine	Spirochrome	Cat#SC008	1 mM stock in DMSO, -80°C
Chemical	Cyclopropene-L-Lysine (CP)	SiChem	Cat#SC-8017	100 mM in 0.2M NaOH+15% DMSO; -80°C
Chemical	Ascorbic Acid	Sigma Aldrich	Cat#A92902	10 mM in ddH <sub>2</sub> O; -20°C
Chemical	mCLING.ATTO488	Synaptic Systems	Cat#710006AT3	Membrane probe, 50µM in ddH <sub>2</sub> O; -80°C
Chemical	Enfuvirtide (T-20)	Roche	NIH AIDS Reagent Program Cat#4624	Fusion inhibitor, 20mM in ddH <sub>2</sub> O; -20°C
Chemical	PF 3450074 (PF74)	Sigma Aldrich	Cat#SML0835	10 mM in DMSO; -20°C
Chemical	Hoechst33258	Merck	Cat#94403	1:1000
Chemical	Polyethylenimine (PEI)	Merck	Cat#408727	Slide coating; 1mg/ml
Chemical	TetraSpeck beads	Thermo Fisher Scientific	Cat#T7279	
Chemical	Aphidicolin	Merck	Cat#178273	Cell cycle arrest
Software, algorithm	Fiji 1.53c	(Schindelin et al. 2012)	RRID:SCR_002285	General image analysis
Software, algorithm	Icy 2.0.3.0	(De Chaumont et al. 2012)	RRID:SCR_010587	Intensity quantification,
Software, algorithm	Prism 8	GraphPad Software Inc. (CA, United States)	RRID:SCR_002798	Visualization and Plotting
Software, algorithm	Seaborn 0.10.0	(Waskom M et al. 2020)	RRID:SCR_018132	Visualization and Plotting
Software, algorithm	Volocity 6.3	Perkin Elmer (United States)	RRID:SCR_002668	Data acquisition
Software, algorithm	Imaris 9.7.2	Bitplane AG (CHE)	RRID:SCR_007370	Spot detection, Intensity quantification
Software, algorithm	Huygens Professional Deconvolution	SVI (NLD)	RRID:SCR_014237	Deconvolution
Software, algorithm	eC-CLEM (Icy plugin; v 1.0.1.5)	(Paul-Gilloteaux et al. 2017)	<a href="http://icy.bioimageanalysis.org/plugin/ec-clem/">http://icy.bioimageanalysis.org/plugin/ec-clem/</a>	Post-correlation
Software, algorithm	SerialEM 3.7.9	(Mastrorade 2005)	RRID:SCR_017293	Tomogram acquisition, Pre-correlation
Software, algorithm	IMOD 4.9.4	(Kremer, Mastrorade, and McIntosh 1996)	RRID:SCR_003297	Tomogram reconstruction
Software, algorithm	Amira 2019.3	Thermo Fisher Scientific	RRID:SCR_007353	Visualization and rendering

713

## 714 List of primers

primer	sequence
Vpr <sub>TGA</sub> fwd	GGAGCCAGTAGATCCTGAACTAGAGCCCTGGTAC
Vpr <sub>TGA</sub> rev	GTACCAGGGCTCTAGTTCAGGATCTACTGGCTCC
CA A14 <sub>BssHII</sub> fwd 1	CTTGCTGAAGCGCGCA
CA A14 <sub>TAG</sub> rev 1	AGTTCTAGGTGATATCTACTGATGTACCATTG

CA A14<sub>TAG</sub> fwd 2  
CA A14<sub>Apal</sub> rev 2

CAAATGGTACATCAGTAGATATCACCTAGAACT  
GCCCTGCAATTTTTGGCTATGTG

715

## 716 **Plasmids**

717 Plasmids were cloned using standard molecular biology techniques and verified by  
718 commercial Sanger sequencing (Eurofins Genomics, GER). PCR was performed using  
719 Q5 High-Fidelity DNA Polymerase (New England Biolabs, GER) or Phusion DNA  
720 Polymerase (New England Biolabs) according to the manufacturer's instructions using  
721 primers purchased from Eurofins Genomics. Plasmid amplification was carried out in  
722 *E. coli* Stbl2 (Thermo Fisher Scientific, USA) cells.

723 HIV-1 plasmids were based on the proviral plasmid pNLC4-3 (Bohne and Kräusslich  
724 2004), expressing the authentic genomic RNA from pNL4-3 (Adachi et al. 1986) under  
725 the control of the cytomegalovirus promoter. To avoid unwanted ncAA incorporation  
726 into the virion component Vpr, the amber stop codon of the *vpr* ORF of pNLC4-3 was  
727 mutated into an opal stop codon (TGA) via site-directed mutagenesis. An EcoRI/StuI  
728 fragment comprising the *vpr* coding region was subcloned from pNLC4-3 into  
729 pcDNA3.1(+) (Thermo Fisher Scientific). Mutagenesis of the *vpr* stop codon was  
730 performed using QuikChange Site-Directed Mutagenesis (Liu and Naismith 2008) with  
731 overlapping primers including the desired mutation (Vpr<sub>TGA</sub> fwd and rev), and the  
732 mutated fragment was transferred back into pNLC4-3 via EcoRI/StuI, resulting in  
733 plasmid pNLC4-3\* (HIV-1\*).

734 The amino acid A14 of the CA coding sequence (GCC) was mutated into TAG via  
735 overlap PCR to obtain a plasmid suitable for click labeling of the CA protein. PCR1  
736 (primers CA14<sub>BssHII</sub> fwd 1, CA14<sub>TAG</sub> rev 1) and PCR2 (primers CA14<sub>TAG</sub> fwd 2, CA14<sub>Apal</sub>  
737 rev 2) were performed in parallel to generate two overlapping single-stranded PCR  
738 products. PCR3 with primers CA14<sub>BssHII</sub> fwd 1 and CA14<sub>Apal</sub> rev 2 result in the PCR  
739 fragment comprising the mutation, which was subcloned into pNLC4-3\* using unique  
740 BssHII/Apal restriction sites, resulting in pNLC4-3\*CA14<sup>TAG</sup> (HIV-1\*CA14<sup>TAG</sup>).

741 Plasmid pNESplyRS-eRF1dn-tRNA (kindly provided by Anna-Lena Schäfer;  
742 Schifferdecker, Sakin et al., in preparation) is based on pEA168 ((Cohen and Arbely  
743 2016); kindly provided by Eyal Arbely, Ben-Gurion University of the Negev, Israel), a  
744 eukaryotic vector that comprises expression cassettes for two proteins and four tRNA  
745 molecules. The coding sequence for a modified pyrrolysine tRNA synthetase was PCR  
746 amplified from plasmid tRNA<sup>Pyl</sup>/NESPyIRS<sup>AF</sup> (Nikić et al. 2016) and cloned into a CMV

747 promoter driven cassette in pEA168 using HindIII/XbaI restriction sites, resulting in  
748 plasmid pEA168-CMV-aaRS-4xU6tRNA. A PCR fragment encoding a dominant  
749 version of the eukaryotic release factor 1 (eRF1(E55D)) amplified from plasmid pERF1-  
750 E55D (Schmied et al. 2014) was subsequently inserted into an expression cassette  
751 driven by the EF1 promoter into pEA168-CMV-aaRS-4xU6tRNA using KpnI/MluI  
752 restriction sites, yielding pNESPLYRS-eRF1dn-tRNA.

753

### 754 **Cell culture**

755 HEK293T (Pear et al. 1993) and HeLa TZM-bl indicator cells (Wei et al. 2002) were  
756 maintained in Dulbecco's Modified Eagle's medium (Thermo Fisher Scientific)  
757 supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin (PAN Biotech, GER)  
758 and 10% fetal calf serum (FCS, Sigma Aldrich, USA). Both cell lines were regularly  
759 monitored for mycoplasma contamination using the MycoAlert mycoplasma detection  
760 kit (Lonza Rockland, USA). Primary CD4<sup>+</sup> T cells were cultured in RPMI 1640  
761 containing L-glutamine supplemented with 100 U/ml penicillin, 100 µg/ml streptomycin  
762 (PAN Biotech), 10% heat-inactivated FCS, and 5% human AB serum (Sigma Aldrich).

763

### 764 **Isolation of primary cells**

765 Primary human CD4<sup>+</sup> T cells were isolated from buffy coats obtained from healthy and  
766 anonymous blood donors at the Heidelberg University Hospital Blood Bank following  
767 the regulations of the local ethics committee. CD4<sup>+</sup> T cells were isolated using  
768 EasySep™ Direct Human T Cell Isolation Kit (Stemcell technologies, GER) according  
769 to the manufacturer's instructions and activated by incubation in the presence of 100  
770 U/ml IL-2 (Sigma Aldrich) and T Cell TransAct™ human (Miltenyi Biotec, GER) for 72  
771 h.

772

### 773 **Virus particle production**

774 HEK293T cells were seeded in T175 tissue culture flasks the day before (~15 Mio.  
775 cells) and transfected using calcium phosphate precipitation according to standard  
776 procedures (~80 % confluency). Cells were co-transfected with 50 µg / flask total DNA  
777 of pNLC4-3\* (HIV-1\*) or pNLC4-3\*CA14<sup>TAG</sup> (HIV-1\*CA14<sup>TAG</sup>) and plasmid  
778 pNESPLYRS-eRF1dn-tRNA in a molar ratio of 2.22:1. At 6 h p.t., medium was removed,  
779 and fresh complete DMEM containing a final concentration of 500 µM CpK (SiChem,  
780 GER; stock solution 100 mM was pre-diluted 1:4 in 1M HEPES shortly before use),

781 and 100  $\mu$ M ascorbic acid (Sigma Aldrich; stock solution 10mM) was added. At 48 h  
782 p.t. the tissue culture supernatant was harvested and filtered through 0.45  $\mu$ m  
783 nitrocellulose filters (Carl Roth, GER). For labeling the CA protein, 250 nM Tetrazine-  
784 SiR (Spirochrome, GER; stock solution 1 mM) was added to the filtered supernatant,  
785 and samples were incubated at 37°C for 30 min. Particles were then concentrated by  
786 ultracentrifugation through a 20% (w/v) sucrose cushion at 28,000 rpm using a  
787 Beckman TLA-100 fixed angle-rotor (Beckman Coulter, GER) for 90 min at 4°C. Pellets  
788 were gently resuspended in phosphate-buffered saline (PBS) containing 10% FCS and  
789 10 mM HEPES (pH 7.5) and stored in 5  $\mu$ l aliquots at -80°C.

790

### 791 **Immunoblotting and In-gel fluorescence**

792 Virus samples were mixed 1:10 with SDS sample buffer (150 mM Tris HCl, pH 6.8, 6%  
793 (w/v) SDS, 30% Glycerin, 0.06% bromophenol blue, 20%  $\beta$ -Mercaptoethanol) and  
794 boiled at 95°C for 15 min. 10  $\mu$ l HIV-1\* and 40  $\mu$ l HIV-1\*CA<sup>SiR</sup> lysates were subjected  
795 to SDS-PAGE (15 %; acrylamide:bis-acrylamide 200:1). Cell lysates were generated  
796 from transfected HEK293T cells. At 40 h p.t. cells were washed with PBS, trypsinized  
797 and resuspended in PBS. 1 ml of cell suspension was mixed with 300  $\mu$ l SDS sample  
798 buffer and boiled at 95°C for 15 min. 10  $\mu$ l cell lysate was subjected to SDS-PAGE.  
799 Proteins were transferred to a nitrocellulose membrane (Millipore, USA) by semi-dry  
800 blotting for 1 h at 0.8 mA/cm<sup>2</sup>. Viral antigens were stained with the indicated antisera  
801 in PBS/0.5% bovine serum albumin (BSA) (sheep $\alpha$ CA, polyclonal 1:5,000 (B. Müller  
802 et al. 2009); rabbit $\alpha$ MA, polyclonal 1:1,000 (in-house); rabbit $\alpha$ RT, polyclonal, 1:1,000  
803 (B. Müller et al. 2004), mouse $\alpha$ laminA/C, monoclonal 1:100 (Santa Cruz  
804 Biotechnology, GER), mouse $\alpha$ laminB1, monoclonal 1:100 (Santa Cruz  
805 Biotechnology)) followed by staining with corresponding secondary antibodies  
806 IRDye™ in PBS/0.5% BSA (anti-sheep 680CW (1;10,000); Rockland, USA and anti-  
807 rabbit 800CW (1:10,000); Li-COR Biosciences, GER). Detection was performed using  
808 a Li-COR Odyssey CLx infrared scanner (Li-COR Biosciences) according to  
809 manufacturer's instructions. CA quantification was performed with ImageStudio LITE  
810 software (Li-COR Biosciences) via intensity measurements of CA bands and a serial  
811 dilution of recombinant CA standard (2.5 ng/ $\mu$ l; in-house) on the same membrane. For  
812 in-gel fluorescence, the acrylamide gels were directly scanned using a Li-COR  
813 Odyssey CLx infrared scanner (Li-COR Biosciences) set at an emission wavelength of  
814 700 nm.

815

## 816 **Infectivity assay**

817 Virus amounts were quantified via SYBR Green based Product Enhanced Reverse  
818 Transcription assay (SG-PERT;(Pizzato et al. 2009)). To determine the effect of  
819 incorporating CpK and Tet-SiR labeling on virus infectivity, HIV-1\* and HIV-1\*CA14<sup>SiR</sup>  
820 viral particles (normalized by RT activity) were titrated on TZM-bl cells seeded in xxx  
821 plates. At 6 h p.i. 50  $\mu$ M T-20 (Enfuvirtide; Roche, GER; stock solution 20 mM) was  
822 added to prevent second-round infection. Infection rates were scored at 48 h p.i.. For  
823 this, cells were fixed in 4% paraformaldehyde (PFA; Electron Microscopy Sciences,  
824 USA; stock solution 16%) for 15 min, followed by 20 min incubation in PBS/0.5% (v/v)  
825 Triton X-100 at room temperature. Immunostaining was performed using an in-house  
826 polyclonal rabbit antiserum raised against recombinant HIV-1 MA (1:1000) in  
827 PBS/0.5% BSA) 1 h at room temperature. Secondary antibody Alexa Fluor 488 donkey  
828 anti-rabbit (1:1,000; Thermo Fisher Scientific) in PBS/0.5% BSA was added for 45 min  
829 at room temperature. Samples were imaged by SDCM. The mean intensity of the 488  
830 channel (MA(IF)) was quantified in from the non-infected samples imaged in parallel  
831 and subtracted as background in each image. The proportion of IF-positive cells was  
832 counted in 12 randomly selected fields of view using Fiji (Schindelin et al. 2012). To  
833 determine the infectivity of virus particle preparations, the number of infected cells per  
834 well was calculated by multiplying the percentage of infected cells detected with the  
835 number of cells per well (double of seeded cell number the day before). Division by the  
836 volume of virus suspension used for infection yielded the number of infectious units  
837 (IU) / ml.

838

## 839 **Fixation and immunofluorescence staining of infected cells**

840  $3.33 \times 10^3$  TZM-bl cells were seeded into 15-well  $\mu$ -Slides Angiogenesis (ibidi, GER;  
841 cat. 81507) the day before infection. Infection at 37°C was performed with an MOI ~0.8  
842 for 6,9,12 or 18 h. Subsequently, cells were incubated for 1 h with 15  $\mu$ M PF74 (Sigma  
843 Aldrich; stock solution 10 mM in DMSO) in DMEM to allow for efficient detection of  
844 nuclear CA by IF (T. G. Müller et al. 2021). Samples were washed with PBS, fixed in  
845 4% PFA for 15 min and permeabilized with PBS/0.5% (v/v) Triton-X100 for 20 min, and  
846 washed again with PBS. Cells were extracted using ice-cold 100% methanol for 10  
847 min. Afterward, samples were blocked with PBS/2.5% BSA for 15 min, followed by  
848 incubation with primary antibodies in PBS/0.5% BSA for 1 h at room temperature. After

849 washing three times with PBS, secondary antibodies diluted in PBS/0.5% BSA were  
850 added for 45 min at room temperature. Samples were washed and stored in PBS at  
851 4°C. For infection of primary CD4<sup>+</sup> T cells, 20,000 cells were infected with HIV-1\* or  
852 HIV-1\*CA14<sup>SiR</sup> in a 96-well v-bottom microplate (Greiner Bio-one, GER; cat. 650161)  
853 in a volume of 40 µl RPMI and transferred at 22 h p.i. onto a PEI-coated 15-well µ-  
854 Slide Angiogenesis (ibidi). Cells were allowed to adhere for 1 h at 37°C, and PF74  
855 diluted in fresh growth medium was added to a final concentration of 15 µM. Extraction,  
856 fixation, and immunostaining were performed after 1 h at 37°C as described above.  
857 For the detection of endosome-associated particles, 2 µM mCLING ATTO488  
858 (Synaptic Systems, GER; stock 50 µM) was added to TZM-bl cells seeded in 15-well  
859 µ-Slides Angiogenesis and incubated at 16°C for 30 min. Subsequently, the fluorescent  
860 probe was removed, HIV-1\*CA14<sup>SiR</sup> particles were added in fresh growth medium, and  
861 cells were incubated for an additional 3 h at 37°C (MOI~0.8). Cells were fixed for 90  
862 min at room temperature in 4% PFA and 0.2% glutaraldehyde to ensure retention of  
863 mCLING at cellular membranes. Nuclei were stained with 5 µg/ml Hoechst (Merck) in  
864 PBS for 30 min.

865

#### 866 **Cell viability assay**

867 To test the effect of mCLING ATTO488 (Synaptic Systems) staining on cell viability,  
868 TZM-bl cells were seeded into a 96-well plate (9x10<sup>3</sup> cells/well; flat bottom Greiner Bio-  
869 one, DE) the day before and incubated in medium supplemented with the indicated  
870 concentration of mCLING ATTO488 for 30 min at 16°C. After staining, cells were  
871 trypsinized and stained with Trypan blue (Strober 2001) using standard procedures  
872 and analyzed with a TC20<sup>TM</sup> Automated Cell Counter (BioRad, GER).

873

#### 874 **Labelling efficiency of immobilized particles**

875 15-well µ-Slide Angiogenesis (ibidi) were coated with 30µl/well polyethyleneimine (PEI;  
876 1mg/ml) for 30 min at room temperature and washed with PBS. Pre-labeled HIV-1\*  
877 and HIV-1\*CA14<sup>SiR</sup> particles were incubated in PBS on PEI-coated microscopy slides  
878 for 1 h at 37°C. Subsequently, samples were washed with PBS, fixed in 4% PFA for  
879 15 min and permeabilized with PBS/0.05% (v/v) Triton X-100 for 20 min at room  
880 temperature. Immobilized particles were blocked with PBS/2.5% BSA for 15 min and  
881 polyclonal rabbit antiserum raised against recombinant HIV-1 CA protein (in-house)  
882 was added (1:1000 in PBS/0.5% BSA for 1 h at room temperature). After washing three



883 times with PBS, secondary antibody Alexa Fluor 488 donkey anti-rabbit (Thermo  
884 Fisher Scientific) 1:1000 in PBS/0.5% BSA was added for 45 min at room temperature.  
885 Samples were washed and stored in PBS at 4°C.

886

### 887 **Confocal microscopy (SDCM)**

888 Multichannel z-series with a z-spacing of 200 nm, spanning the whole cell volume (3D),  
889 were acquired using a PerkinElmer Ultra VIEW VoX 3D spinning disk confocal  
890 microscope (SDCM; Perkin Elmer, MA, USA). A 60x oil immersion objective (numeric  
891 aperture [NA] 1.49; Perkin Elmer) was used for imaging of TZM-bl cells or 100x oil  
892 immersion objective ([NA] 1.49; Perkin Elmer) for primary CD4+ T cells and  
893 immobilized particles. Images were recorded in the 405-, 488-, 561-, and 640 nm  
894 channels.

895

### 896 **STED microscopy**

897 STED nanoscopy was performed using a  $\lambda = 775$  nm STED system (Abberior  
898 Instruments GmbH, GER) equipped with a 100x oil immersion objective (NA 1.4;  
899 Olympus UPlanSApo). STED images were acquired using the 640 nm excitation laser  
900 lines while the 488 and 590 laser line was acquired in confocal mode only. Nominal  
901 STED laser power was set to 20% of the maximal power (1250 mW) with pixel dwell  
902 time of 10  $\mu$ s and 15 nm pixel size. STED images were deconvolved using the software  
903 Inspector (Abberior Instruments GmbH) and Huygens Professional Deconvolution  
904 (Scientific Volume Imaging, NED).

905

### 906 **Electron microscopy**

907 HEK293T cells ( $4 \times 10^5$ ) were seeded in a glass coverslip-bottom petri dish (MatTek,  
908 MA, USA), cultured for 16 h at 37°C and then co-transfected with pNLC4-3\*CA14<sup>TAG</sup>  
909 and pNESPIyRS-eRF1dn-tRNA by using calcium phosphate precipitation. At 6 h p.t.,  
910 medium was removed and fresh complete DMEM containing a final concentration of  
911 500  $\mu$ M CpK (SiChem, GER; stock solution 100 mM was pre-diluted 1:4 in 1M HEPES  
912 shortly before use), and 100  $\mu$ M ascorbic acid (Sigma Aldrich; stock solution 10mM)  
913 was added. At 44 h p.t., cells were fixed with pre-warmed 2% formaldehyde + 2.5%  
914 glutaraldehyde in 0.1M cacodylate buffer (pH 7.4) for 1.5 h at room temperature, then  
915 washed in 0.1M cacodylate buffer and post-fixed with 2% osmium tetroxide (Electron  
916 Microscopy Sciences) for a 1 h on ice. Cells were subsequently dehydrated through

917 an increasing cold ethanol series (30, 50, 70, 80, 90, and 100%; on ice) and two  
918 anhydrous acetone series (at room temperature). The coverslip with cells was then  
919 removed from the dish, and cells were flat embedded in Epon resin. 70-nm thin  
920 sections were cut with an ultramicrotome (Leica EM UC6), collected on formvar-coated  
921 100-mesh copper EM grids (Electron Microscopy Sciences) and stained with a 3%  
922 uranyl acetate in 70% MeOH (10 min), and lead citrate (7 min). Cells sections were  
923 observed with a JEOL JEM-1400 electron microscope operating at 80 kV (Jeol Ltd.,  
924 JPN), equipped with a bottom-mounted 4K by 4K pixel digital camera (TemCam F416;  
925 TVIPS GmbH, GER).

926

### 927 **CLEM and electron tomography**

928 SupT1 cells were distributed in a 96-well plate ( $2 \times 10^5$  cells/well; U-bottom; Greiner Bio-  
929 one, 650180) and pre-incubated for 16 h with  $1 \mu\text{m}$  aphidicolin (APC; Merck). Cells  
930 were pelleted (200 x g, 3 min) and resuspended in complete RPMI medium containing  
931 HIV-1\*CA14<sup>SIR</sup> particles (MOI~0.4). Cells were incubated with viral particles for 120  
932 min at 16°C to adsorb the virus and synchronize virus entry. Samples were then  
933 processed for CLEM and ET as described previously (Zila et al. 2021). In brief, cells  
934 were transferred to glass-bottomed ‘microwell’ of MatTek dish (MatTek, USA)  
935 containing carbon-coated and retronectin-coated sapphire discs (Engineering Office  
936 M. Wohlwend, SUI). Samples were high pressure frozen, and sapphire discs were then  
937 transferred from liquid nitrogen to the freeze-substitution (FS) medium (0.1% uranyl  
938 acetate, 2.3% methanol and 2% H<sub>2</sub>O in acetone) tempered at -90°C. Samples were  
939 FS-processed and embedded in Lowicryl HM20 resin (Polysciences, USA) according  
940 to a modified protocol of Kukulski et al. (Kukulski et al. 2011). For CLEM-ET, thick resin  
941 sections (250 nm) were cut and placed on a slot (1 × 2 mm) EM copper grids covered  
942 with a formvar film (Electron Microscopy Sciences, FF2010-Cu). Grids were decorated  
943 with fiducial marker and stained with Hoechst to visualize nuclear regions. Light  
944 microscopy Z stacks of sections were acquired by PerkinElmer UltraVIEW VoX 3D  
945 Spinning-disc Confocal Microscope (Perkin Elmer) using a 100 × oil immersion  
946 objective (NA 1.49; Nikon), with a z-spacing of 200 nm and excitation with the 405-,  
947 488-, 561- and 633-nm laser line. Acquired z stacks were visually examined using Fiji  
948 software (Schindelin et al. 2012) and intracellular CA(SiR) positive signals were  
949 identified. EM grids were decorated with 15 nm protein-A gold particles for tomogram  
950 alignment and stained with uranyl acetate and lead citrate. Grids were loaded to a

951 Tecnai TF20 (FEI) electron microscope (operated at 200 kV) equipped with a field  
952 emission gun and a 4K by 4K pixel Eagle CCD camera (FEI). Positions of CA(SiR)  
953 signals were pre-correlated with imported SDCM images in SerialEM (Mastronarde  
954 2005) as described previously (Schorb et al. 2017). Single-axis electron tomograms  
955 were carried out. Tomographic tilt ranges were typically from  $-60^\circ$  to  $60^\circ$  with an  
956 angular increment of  $1^\circ$ . The pixel size was 1.13 nm. Alignments and 3D  
957 reconstructions of tomograms were done with IMOD software (Kremer, Mastronarde,  
958 and McIntosh 1996). Post-correlation was performed using eC-CLEM plugin (Paul-  
959 Gilloteaux et al. 2017) in Icy software (De Chaumont et al. 2012).

960

### 961 **Image analysis**

962 Microscopy images were screened and filtered in Fiji/ImageJ (Schindelin et al. 2012)  
963 with a mean filter and background subtraction. Infected cells were quantified in Fiji via  
964 segmentation and counting of nuclei and the cell counter to manually quantify the  
965 number of positive cells.

966 To determine labeling efficiency of click labeled particles, CA(SiR) intensities of  
967 detected immobilized particles based on CA(IF) were quantified using the spot detector  
968 of the software Icy (De Chaumont et al. 2012). 5 ROIs without particles were measured  
969 and mean intensity in the SiR channel was subtracted as background. Threshold was  
970 set to  $t = 1,000$  a.u.. Every CA(IF) detected spot above was considered CA(SiR)  
971 positive.

972 To analyze particle distribution and intensity measurements throughout the entire  
973 volume of cells, z-image series were reconstructed in 3D space using Imaris 9.2  
974 software (Bitplane AG, SUI). Individual HIV-1 CA(IF) objects were automatically  
975 detected using the spot detector Imaris module, which created for each fluorescent  
976 signal a 3D ellipsoid object with 300 nm estimated diameter in x-y dimensions and 600  
977 nm in z. The local background of each individual spot was subtracted automatically.  
978 Subsequently, the mean signal intensity in the CA(SiR) channel was quantitated within  
979 all objects. The threshold for SiR intensity was set to  $t = 7,000$  a.u. and adjusted  
980 manually for each image by visual inspection. Spots detected in SiR-clusters were  
981 excluded. Nuclear objects were manually identified based on the laminA/C staining.  
982 NE-associated objects were classified based on laminA/C intensities. Every image was  
983 manually inspected and a threshold for NE-associated objects was set in the range of

984 6,300-9,100 a.u.. All other particles were classified as PM/cytoplasm (= in the  
985 cytoplasm/at plasma membrane).

986 To identify post-fusion cores by mCLING ATTO488 staining, HIV-1 CA(SiR) positive  
987 objects were automatically detected and the mCLING ATTO488 mean signal intensity  
988 co-localizing with each object was quantitated. The threshold was set to  $t = 5,900$  a.u.  
989 based on the lowest mCLING intensity detected in a T-20 control sample. Particles  
990 associated with mCLING intensity above background were classified as endosome  
991 associated. Fiji standard 'greyscale' lookup table (LUT) was used to visualize single  
992 channel images and 'Fire' for single channel STED images.

993

#### 994 **Data visualization and statistical analysis**

995 Statistical significance was assessed using Prism v9.1.0 (GraphPad Software Inc,  
996 USA). A two-tailed non-paired Mann-Whitney test ( $\alpha = 0.05$ ) was used to assess the  
997 statistical significance of non-parametric data. Data were plotted using Prism v9.1.0 or  
998 the Python statistical data visualization package seaborn v.0.10.0 (Waskom et al.,  
999 2020). Graphs show mean/median with error bars as defined in the figure legends.

1000

1001 **Competing financial interests:** The authors declare no competing financial interests.

1002

#### 1003 **References**

1004 Adachi, A, H E Gendelman, S Koenig, T Folks, R Willey, A Rabson, and M A Martin.  
1005 1986. "Production of Acquired Immunodeficiency Syndrome-Associated  
1006 Retrovirus in Human and Nonhuman Cells Transfected with an Infectious  
1007 Molecular Clone." *Journal of Virology* 59 (2): 284–91.  
1008 <https://doi.org/10.1128/jvi.59.2.284-291.1986>.

1009 Arhel, Nathalie J., Sylvie Souquere-Besse, Sandie Munier, Philippe Souque,  
1010 Stéphanie Guadagnini, Sandra Rutherford, Marie Christine Prévost, Terry D.  
1011 Allen, and Pierre Charneau. 2007. "HIV-1 DNA Flap Formation Promotes  
1012 Uncoating of the Pre-Integration Complex at the Nuclear Pore." *EMBO Journal* 26  
1013 (12): 3025–37. <https://doi.org/10.1038/sj.emboj.7601740>.

1014 Asokan, Aravind, David V. Schaffer, and R. Jude Samulski. 2012. "The AAV Vector  
1015 Toolkit: Poised at the Clinical Crossroads." *Molecular Therapy* 20 (4): 699–708.  
1016 <https://doi.org/10.1038/mt.2011.287>.

- 1017 Balzarotti, Francisco, Yvan Eilers, Klaus C Gwosch, Arvid H Gynnå, Volker Westphal,  
1018 Fernando D Stefani, Johan Elf, and Stefan W Hell. 2017. "With Minimal Photon  
1019 Fluxes." *Science* 355 (February): 606–12.  
1020 <https://doi.org/10.1126/science.aak9913>.
- 1021 Bhattacharya, Akash, Steven L. Alam, Thomas Fricke, Kaneil Zadrozny, Jaroslaw  
1022 Sedzicki, Alexander B. Taylor, Borries Demeler, et al. 2014. "Structural Basis of  
1023 HIV-1 Capsid Recognition by PF74 and CPSF6." *Proceedings of the National  
1024 Academy of Sciences* 111 (52): 18625–30.  
1025 <https://doi.org/10.1073/pnas.1419945112>.
- 1026 Blair, Wade S., Chris Pickford, Stephen L. Irving, David G. Brown, Marie Anderson,  
1027 Richard Bazin, Joan Cao, et al. 2010. "HIV Capsid Is a Tractable Target for Small  
1028 Molecule Therapeutic Intervention." *PLoS Pathogens* 6 (12).  
1029 <https://doi.org/10.1371/journal.ppat.1001220>.
- 1030 Blanco-Rodriguez, Guillermo, Anastasia Gazi, Blandine Monel, Stella Frabetti, Viviana  
1031 Scoca, Florian Mueller, Olivier Schwartz, Jacomine Krijnse-Locker, Pierre  
1032 Charneau, and Francesca Di Nunzio. 2020. "Remodeling of the Core Leads HIV-  
1033 1 Preintegration Complex into the Nucleus of Human Lymphocytes." *Journal of  
1034 Virology* 94 (11). <https://doi.org/10.1128/jvi.00135-20>.
- 1035 Bohne, Jens, and Hans Georg Kräusslich. 2004. "Mutation of the Major 5' Splice Site  
1036 Renders a CMV-Driven HIV-1 Proviral Clone Tat-Dependent: Connections  
1037 between Transcription and Splicing." *FEBS Letters* 563 (1–3): 113–18.  
1038 [https://doi.org/10.1016/S0014-5793\(04\)00277-7](https://doi.org/10.1016/S0014-5793(04)00277-7).
- 1039 Börner, Kathleen, Eike Kienle, Lin Ya Huang, Jonas Weinmann, Anna Sacher, Philipp  
1040 Bayer, Christian Stülle, et al. 2020. "Pre-Arrayed Pan-AAV Peptide Display  
1041 Libraries for Rapid Single-Round Screening." *Molecular Therapy* 28 (4): 1016–32.  
1042 <https://doi.org/10.1016/j.ymthe.2020.02.009>.
- 1043 Briggs, J. A G, Martha N. Simon, Ingolf Gross, Hans Georg Kräusslich, Stephen D.  
1044 Fuller, Volker M. Vogt, and Marc C. Johnson. 2004. "The Stoichiometry of Gag  
1045 Protein in HIV-1." *Nature Structural and Molecular Biology* 11 (7): 672–75.  
1046 <https://doi.org/10.1038/nsmb785>.
- 1047 Briggs, John A.G., Thomas Wilk, Reinhold Welker, Hans Georg Kräusslich, and  
1048 Stephen D. Fuller. 2003. "Structural Organization of Authentic, Mature HIV-1

- 1049 Virions and Cores.” *EMBO Journal* 22 (7): 1707–15.  
1050 <https://doi.org/10.1093/emboj/cdg143>.
- 1051 Bukrinsky, Michael I., Sheryl Haggerty, Michael P. Dempsey, Natalia Sharova, Alexei  
1052 Adzhubei, Lynn Spitz, Paul Lewis, David Goldfarb, Michael Emerman, and Mario  
1053 Stevenson. 1993. “A Nuclear Localization Signal within HIV-1 Matrix Protein That  
1054 Governs Infection of Non-Dividing Cells.” *Nature* 365 (6447): 666–69.  
1055 <https://doi.org/10.1038/365666a0>.
- 1056 Burdick, Ryan C., Krista A. Delviks-Frankenberry, Jianbo Chen, Sanath K. Janaka,  
1057 Jaya Sastri, Wei Shau Hu, and Vinay K. Pathak. 2017. *Dynamics and Regulation*  
1058 *of Nuclear Import and Nuclear Movements of HIV-1 Complexes. PLoS Pathogens.*  
1059 Vol. 13. <https://doi.org/10.1371/journal.ppat.1006570>.
- 1060 Burdick, Ryan C., Chenglei Li, Mohamed Husen Munshi, Jonathan M.O. Rawson,  
1061 Kunio Nagashima, Wei Shau Hu, and Vinay K. Pathak. 2020. “HIV-1 Uncoats in  
1062 the Nucleus near Sites of Integration.” *Proceedings of the National Academy of*  
1063 *Sciences of the United States of America* 117 (10): 5486–93.  
1064 <https://doi.org/10.1073/pnas.1920631117>.
- 1065 Campbell, Edward M., and Thomas J. Hope. 2015. “HIV-1 Capsid: The Multifaceted  
1066 Key Player in HIV-1 Infection.” *Nature Reviews Microbiology* 13 (8): 471–83.  
1067 <https://doi.org/10.1038/nrmicro3503>.
- 1068 Campbell, Edward M., Omar Perez, Jenny L. Anderson, and Thomas J. Hope. 2008.  
1069 “Visualization of a Proteasome-Independent Intermediate during Restriction of  
1070 HIV-1 by Rhesus TRIM5 $\alpha$ .” *Journal of Cell Biology* 180 (3): 549–61.  
1071 <https://doi.org/10.1083/jcb.200706154>.
- 1072 Carlson, Lars Anders, John A.G. Briggs, Bärbel Glass, James D. Riches, Martha N.  
1073 Simon, Marc C. Johnson, Barbara Müller, Kay Grünewald, and Hans Georg  
1074 Kräusslich. 2008. “Three-Dimensional Analysis of Budding Sites and Released  
1075 Virus Suggests a Revised Model for HIV-1 Morphogenesis.” *Cell Host and*  
1076 *Microbe* 4 (6): 592–99. <https://doi.org/10.1016/j.chom.2008.10.013>.
- 1077 Chaumont, Fabrice De, Stéphane Dallongeville, Nicolas Chenouard, Nicolas Hervé,  
1078 Sorin Pop, Thomas Provoost, Vannary Meas-Yedid, et al. 2012. “Icy: An Open  
1079 Bioimage Informatics Platform for Extended Reproducible Research.” *Nature*  
1080 *Methods* 9 (7): 690–96. <https://doi.org/10.1038/nmeth.2075>.

- 1081 Chen, Nan Yu, Lihong Zhou, Paul J. Gane, Silvana Opp, Neil J. Ball, Giuseppe  
1082 Nicastro, Madeleine Zufferey, et al. 2016. "HIV-1 Capsid Is Involved in Post-  
1083 Nuclear Entry Steps." *Retrovirology* 13 (1): 1–16. [https://doi.org/10.1186/s12977-](https://doi.org/10.1186/s12977-016-0262-0)  
1084 016-0262-0.
- 1085 Cohen, Sarit, and Eyal Arbely. 2016. "Single-Plasmid-Based System for Efficient  
1086 Noncanonical Amino Acid Mutagenesis in Cultured Mammalian Cells."  
1087 *ChemBioChem* 17 (11): 1008–11. <https://doi.org/10.1002/cbic.201500681>.
- 1088 Cosnefroy, Ophélie, Philip J. Murray, and Kate N. Bishop. 2016. "HIV-1 Capsid  
1089 Uncoating Initiates after the First Strand Transfer of Reverse Transcription."  
1090 *Retrovirology* 13 (1): 1–17. <https://doi.org/10.1186/s12977-016-0292-7>.
- 1091 Dharan, Adarsh, Niklas Bachmann, Sarah Talley, Virginia Zwickelmaier, and Edward M.  
1092 Campbell. 2020. "Nuclear Pore Blockade Reveals That HIV-1 Completes Reverse  
1093 Transcription and Uncoating in the Nucleus." *Nature Microbiology* 5 (9): 1088–95.  
1094 <https://doi.org/10.1038/s41564-020-0735-8>.
- 1095 Engelman, Alan N. 2021. "Hiv Capsid and Integration Targeting." *Viruses* 13 (1): 1–14.  
1096 <https://doi.org/10.3390/v13010125>.
- 1097 Erdmann, Roman S., Hideo Takakura, Alexander D. Thompson, Felix Rivera-Molina,  
1098 Edward S. Allgeyer, Joerg Bewersdorf, Derek Toomre, and Alanna Schepartz.  
1099 2014. "Super-Resolution Imaging of the Golgi in Live Cells with a Bioorthogonal  
1100 Ceramide Probe." *Angewandte Chemie - International Edition* 53 (38): 10242–46.  
1101 <https://doi.org/10.1002/anie.201403349>.
- 1102 Fassati, Ariberto. 2012. "Multiple Roles of the Capsid Protein in the Early Steps of HIV-  
1103 1 Infection." *Virus Research* 170 (1–2): 15–24.  
1104 <https://doi.org/10.1016/j.virusres.2012.09.012>.
- 1105 Fassati, Ariberto, and Sp Goff. 2001. "Characterization of Intracellular Reverse  
1106 Transcription Complexes of Human Immunodeficiency Virus Type 1." *Journal of*  
1107 *Virology* 75 (8): 3626–35. <https://doi.org/10.1128/JVI.75.8.3626>.
- 1108 Fernandez, Juliette, Anthony K. Machado, Sébastien Lyonnais, Célia Chamontin,  
1109 Kathleen Gärtner, Thibaut Léger, Corinne Henriquet, et al. 2019. "Transportin-1  
1110 Binds to the HIV-1 Capsid via a Nuclear Localization Signal and Triggers  
1111 Uncoating." *Nature Microbiology* 4 (11): 1840–50. [https://doi.org/10.1038/s41564-](https://doi.org/10.1038/s41564-019-0575-6)  
1112 019-0575-6.

- 1113 Francis, Ashwanth C., Mariana Marin, Mathew J. Prellberg, Kristina Palermino-  
1114 Rowland, and Gregory B. Melikyan. 2020. "Hiv-1 Uncoating and Nuclear Import  
1115 Precede the Completion of Reverse Transcription in Cell Lines and in Primary  
1116 Macrophages." *Viruses* 12 (11): 1–22. <https://doi.org/10.3390/v12111234>.
- 1117 Francis, Ashwanth C., Mariana Marin, Jiong Shi, Christopher Aiken, and Gregory B.  
1118 Melikyan. 2016. "Time-Resolved Imaging of Single HIV-1 Uncoating In Vitro and  
1119 in Living Cells." *PLoS Pathogens* 12 (6): 1–28.  
1120 <https://doi.org/10.1371/journal.ppat.1005709>.
- 1121 Francis, Ashwanth C., Mariana Marin, Parmit K. Singh, Vasudevan Achuthan, Mathew  
1122 J. Prellberg, Kristina Palermino-Rowland, Shuiyun Lan, et al. 2020. "HIV-1  
1123 Replication Complexes Accumulate in Nuclear Speckles and Integrate into  
1124 Speckle-Associated Genomic Domains." *Nature Communications* 11 (1).  
1125 <https://doi.org/10.1038/s41467-020-17256-8>.
- 1126 Francis, Ashwanth C., and Gregory B. Melikyan. 2018. "Single HIV-1 Imaging Reveals  
1127 Progression of Infection through CA-Dependent Steps of Docking at the Nuclear  
1128 Pore, Uncoating, and Nuclear Transport." *Cell Host and Microbe* 23 (4): 536-  
1129 548.e6. <https://doi.org/10.1016/j.chom.2018.03.009>.
- 1130 Ganser-Pornillos, Barbie K., Anchi Cheng, and Mark Yeager. 2007. "Structure of Full-  
1131 Length HIV-1 CA: A Model for the Mature Capsid Lattice." *Cell* 131 (1): 70–79.  
1132 <https://doi.org/10.1016/j.cell.2007.08.018>.
- 1133 Golding, Hana, Marina Zaitseva, Eve de Rosny, Lisa R. King, Jody Manischewitz, Igor  
1134 Sidorov, Mirosław K. Gorny, Susan Zolla-Pazner, Dimitar S. Dimitrov, and Carol  
1135 D. Weiss. 2002. "Dissection of Human Immunodeficiency Virus Type 1 Entry with  
1136 Neutralizing Antibodies to Gp41 Fusion Intermediates." *Journal of Virology* 76  
1137 (13): 6780–90. <https://doi.org/10.1128/jvi.76.13.6780-6790.2002>.
- 1138 Grime, John M.A., and Gregory A. Voth. 2012. "Early Stages of the HIV-1 Capsid  
1139 Protein Lattice Formation." *Biophysical Journal* 103 (8): 1774–83.  
1140 <https://doi.org/10.1016/j.bpj.2012.09.007>.
- 1141 Grimm, Dirk, and Sergei Zolotukhin. 2015. "E Pluribus Unum: 50 Years of Research,  
1142 Millions of Viruses, and One Goal-Tailored Acceleration of AAV Evolution."  
1143 *Molecular Therapy* 23 (12): 1819–31. <https://doi.org/10.1038/mt.2015.173>.
- 1144 Guedán, Anabel, Eve R Caroe, Genevieve C R Barr, and Kate N Bishop. 2021. "The



- 1145           Role of Capsid in HIV-1 Nuclear Entry,” 1–14.
- 1146 Heilemann, Mike, Sebastian Van De Linde, Mark Schüttpelz, Robert Kasper, Britta  
1147           Seefeldt, Anindita Mukherjee, Philip Tinnefeld, and Markus Sauer. 2008.  
1148           “Subdiffraction-Resolution Fluorescence Imaging with Conventional Fluorescent  
1149           Probes.” *Angewandte Chemie - International Edition* 47 (33): 6172–76.  
1150           <https://doi.org/10.1002/anie.200802376>.
- 1151 Hulme, Amy E., and Thomas J. Hope. 2014. “The Cyclosporin A Washout Assay to  
1152           Detect HIV-1 Uncoating in Infected Cells.” In , 37–46. [https://doi.org/10.1007/978-](https://doi.org/10.1007/978-1-62703-670-2_4)  
1153           1-62703-670-2\_4.
- 1154 Hulme, Amy E., Omar Perez, and Thomas J. Hope. 2011. “Complementary Assays  
1155           Reveal a Relationship between HIV-1 Uncoating and Reverse Transcription.”  
1156           *Proceedings of the National Academy of Sciences of the United States of America*  
1157           108 (24): 9975–80. <https://doi.org/10.1073/pnas.1014522108>.
- 1158 Kane, Melissa, Stephanie V. Rebensburg, Matthew A. Takata, Trinity M. Zang,  
1159           Masahiro Yamashita, Mamuka Kvaratskhelia, and Paul D. Bieniasz. 2018.  
1160           “Nuclear Pore Heterogeneity Influences HIV-1 Infection and the Antiviral Activity  
1161           of MX2.” *ELife* 7: 1–44. <https://doi.org/10.7554/eLife.35738>.
- 1162 Katrekar, Dhruva, Ana M. Moreno, Genghao Chen, Atharv Worlikar, and Prashant  
1163           Mali. 2018. “Oligonucleotide Conjugated Multi-Functional Adeno-Associated  
1164           Viruses.” *Scientific Reports* 8 (1): 1–8. [https://doi.org/10.1038/s41598-018-21742-](https://doi.org/10.1038/s41598-018-21742-x)  
1165           x.
- 1166 Kelemen, Rachel E., Sarah B. Erickson, and Abhishek Chatterjee. 2018. “Synthesis at  
1167           the Interface of Virology and Genetic Code Expansion.” *Current Opinion in*  
1168           *Chemical Biology* 46: 164–71. <https://doi.org/10.1016/j.cbpa.2018.07.015>.
- 1169 Klar, Thomas A., and Stefan W. Hell. 1999. “Subdiffraction Resolution in Far-Field  
1170           Fluorescence Microscopy.” *Optics Letters* 24 (14): 954.  
1171           <https://doi.org/10.1364/OL.24.000954>.
- 1172 Knockenhauer, Kevin E., and Thomas U. Schwartz. 2016. “The Nuclear Pore Complex  
1173           as a Flexible and Dynamic Gate.” *Cell* 164 (6): 1162–71.  
1174           <https://doi.org/10.1016/j.cell.2016.01.034>.
- 1175 Kotterman, Melissa A., and David V. Schaffer. 2014. “Engineering Adeno-Associated  
1176           Viruses for Clinical Gene Therapy.” *Nature Reviews Genetics* 15 (7): 445–51.

- 1177 <https://doi.org/10.1038/nrg3742>.
- 1178 Krauskopf, Kristina, and Kathrin Lang. 2020. "Increasing the Chemical Space of  
1179 Proteins in Living Cells via Genetic Code Expansion." *Current Opinion in Chemical*  
1180 *Biology* 58: 112–20. <https://doi.org/10.1016/j.cbpa.2020.07.012>.
- 1181 Kremer, James R., David N. Mastronarde, and J. Richard McIntosh. 1996. "Computer  
1182 Visualization of Three-Dimensional Image Data Using IMOD." *Journal of*  
1183 *Structural Biology* 116 (1): 71–76. <https://doi.org/10.1006/jsbi.1996.0013>.
- 1184 Kukulski, Wanda, Martin Schorb, Sonja Welsch, Andrea Picco, Marko Kaksonen, and  
1185 John A.G. Briggs. 2011. "Correlated Fluorescence and 3D Electron Microscopy  
1186 with High Sensitivity and Spatial Precision." *Journal of Cell Biology* 192 (1): 111–  
1187 19. <https://doi.org/10.1083/jcb.201009037>.
- 1188 la Torre, Daniel de, and Jason W. Chin. 2021. "Reprogramming the Genetic Code."  
1189 *Nature Reviews Genetics* 22 (3): 169–84. [https://doi.org/10.1038/s41576-020-](https://doi.org/10.1038/s41576-020-00307-7)  
1190 [00307-7](https://doi.org/10.1038/s41576-020-00307-7).
- 1191 Lang, Kathrin, and Jason W. Chin. 2014. "Bioorthogonal Reactions for Labeling  
1192 Proteins." *ACS Chemical Biology* 9 (1): 16–20.  
1193 <https://doi.org/10.1021/cb4009292>.
- 1194 Lanman, Jason, Tu Kiet T. Lam, Mark R. Emmett, Alan G. Marshall, Michael Sakalian,  
1195 and Peter E. Prevelige. 2004. "Key Interactions in HIV-1 Maturation Identified by  
1196 Hydrogen-Deuterium Exchange." *Nature Structural and Molecular Biology* 11 (7):  
1197 676–77. <https://doi.org/10.1038/nsmb790>.
- 1198 Lee, K., A. Mulky, W. Yuen, T. D. Martin, N. R. Meyerson, L. Choi, H. Yu, S. L. Sawyer,  
1199 and V. N. KewalRamani. 2012. "HIV-1 Capsid-Targeting Domain of Cleavage and  
1200 Polyadenylation Specificity Factor 6." *Journal of Virology* 86 (7): 3851–60.  
1201 <https://doi.org/10.1128/jvi.06607-11>.
- 1202 Lelek, Mickaël, Nicoletta Casartelli, Danilo Pellin, Ermanno Rizzi, Philippe Souque,  
1203 Marco Severgnini, Clelia Di Serio, et al. 2015. "Chromatin Organization at the  
1204 Nuclear Pore Favours HIV Replication." *Nature Communications* 6.  
1205 <https://doi.org/10.1038/ncomms7483>.
- 1206 Li, Chenglei, Ryan C. Burdick, Kunio Nagashima, Wei-Shau Hu, and Vinay K. Pathak.  
1207 2021. "HIV-1 Cores Retain Their Integrity until Minutes before Uncoating in the  
1208 Nucleus." *Proceedings of the National Academy of Sciences* 118 (10):

- 1209 e2019467118. <https://doi.org/10.1073/pnas.2019467118>.
- 1210 Liu, Huanting, and James H. Naismith. 2008. "An Efficient One-Step Site-Directed  
1211 Deletion, Insertion, Single and Multiple-Site Plasmid Mutagenesis Protocol." *BMC*  
1212 *Biotechnology* 8: 91. <https://doi.org/10.1186/1472-6750-8-91>.
- 1213 Lukic, Zana, Adarsh Dharan, Thomas Fricke, Felipe Diaz-Griffero, and Edward M.  
1214 Campbell. 2014. "HIV-1 Uncoating Is Facilitated by Dynein and Kinesin 1." *Journal*  
1215 *of Virology* 88 (23): 13613–25. <https://doi.org/10.1128/jvi.02219-14>.
- 1216 Lukinavičius, Gražvydas, Keitaro Umezawa, Nicolas Olivier, Alf Honigmann, Guoying  
1217 Yang, Tilman Plass, Veronika Mueller, et al. 2013. "A Near-Infrared Fluorophore  
1218 for Live-Cell Super-Resolution Microscopy of Cellular Proteins." *Nature Chemistry*  
1219 5 (2): 132–39. <https://doi.org/10.1038/nchem.1546>.
- 1220 Ma, Yingxin, Zhike He, Tianwei Tan, Wei Li, Zhiping Zhang, Shuang Song, Xiaowei  
1221 Zhang, et al. 2016. "Real-Time Imaging of Single HIV-1 Disassembly with  
1222 Multicolor Viral Particles." *ACS Nano* 10 (6): 6273–82.  
1223 <https://doi.org/10.1021/acsnano.6b02462>.
- 1224 Mamede, João I., Gianguido C. Cianci, Meegan R. Anderson, and Thomas J. Hope.  
1225 2017. "Early Cytoplasmic Uncoating Is Associated with Infectivity of HIV-1."  
1226 *Proceedings of the National Academy of Sciences of the United States of America*  
1227 114 (34): E7169–78. <https://doi.org/10.1073/pnas.1706245114>.
- 1228 Márquez, Chantal L, Derrick Lau, James Walsh, Vaibhav Shah, Conall McGuinness,  
1229 Andrew Wong, Anupriya Aggarwal, et al. 2018. "Kinetics of HIV-1 Capsid  
1230 Uncoating Revealed by Single-Molecule Analysis." *ELife* 7: e34772.  
1231 <https://doi.org/10.7554/eLife.34772>.
- 1232 Marsh, Mark, and Ari Helenius. 2006. "Virus Entry: Open Sesame." *Cell* 124 (4): 729–  
1233 40. <https://doi.org/10.1016/j.cell.2006.02.007>.
- 1234 Mastronarde, David N. 2005. "Automated Electron Microscope Tomography Using  
1235 Robust Prediction of Specimen Movements." *Journal of Structural Biology* 152 (1):  
1236 36–51. <https://doi.org/10.1016/j.jsb.2005.07.007>.
- 1237 Matreyek, Kenneth A., Sara S. Yücel, Xiang Li, and Alan Engelman. 2013.  
1238 "Nucleoporin NUP153 Phenylalanine-Glycine Motifs Engage a Common Binding  
1239 Pocket within the HIV-1 Capsid Protein to Mediate Lentiviral Infectivity." *PLoS*  
1240 *Pathogens* 9 (10). <https://doi.org/10.1371/journal.ppat.1003693>.

- 1241 Mattei, Simone, Bärbel Glass, Wim J.H. Hagen, Hans Georg Kräusslich, and John A.G.  
1242 Briggs. 2016. "The Structure and Flexibility of Conical HIV-1 Capsids Determined  
1243 within Intact Virions." *Science* 354 (6318): 1434–37.  
1244 <https://doi.org/10.1126/science.aah4972>.
- 1245 McArthur, Carole, Fabio Gallazzi, Thomas P. Quinn, and Kamal Singh. 2019. "HIV  
1246 Capsid Inhibitors Beyond PF74." *Diseases* 7 (4): 56.  
1247 <https://doi.org/10.3390/diseases7040056>.
- 1248 Melikyan, Gregory B. 2014. "HIV Entry: A Game of Hide-and-Fuse?" *Current Opinion*  
1249 *in Virology* 4 (2): 1–7. <https://doi.org/10.1016/j.coviro.2013.09.004>.
- 1250 Melikyan, Grigory B., Ruben M. Markosyan, Hila Hemmati, Mary K. Delmedico, Dennis  
1251 M. Lambert, and Fredric S. Cohen. 2000. "Evidence That the Transition of HIV-1  
1252 Gp41 into a Six-Helix Bundle, Not the Bundle Configuration, Induces Membrane  
1253 Fusion." *Journal of Cell Biology* 151 (2): 413–23.  
1254 <https://doi.org/10.1083/jcb.151.2.413>.
- 1255 Miller, M D, C M Farnet, and F D Bushman. 1997. "Human Immunodeficiency Virus  
1256 Type 1 Preintegration Complexes: Studies of Organization and Composition."  
1257 *Journal of Virology* 71 (7): 5382–90. [https://doi.org/10.1128/jvi.71.7.5382-](https://doi.org/10.1128/jvi.71.7.5382-5390.1997)  
1258 [5390.1997](https://doi.org/10.1128/jvi.71.7.5382-5390.1997).
- 1259 Müller, Barbara, Maria Anders, Hisashi Akiyama, Sonja Welsch, Bärbel Glass,  
1260 Krisztina Nikovics, Francois Clavel, Hanna Mari Tervo, Oliver T. Keppler, and  
1261 Hans Georg Kräusslich. 2009. "HIV-1 Gag Processing Intermediates Trans-  
1262 Dominantly Interfere with HIV-1 Infectivity." *Journal of Biological Chemistry* 284  
1263 (43): 29692–703. <https://doi.org/10.1074/jbc.M109.027144>.
- 1264 Müller, Barbara, Jessica Daecke, Oliver T. Fackler, Matthias T. Dittmar, Hanswalter  
1265 Zentgraf, and Hans-Georg Kräusslich. 2004. "Construction and Characterization  
1266 of a Fluorescently Labeled Infectious Human Immunodeficiency Virus Type 1  
1267 Derivative." *Journal of Virology* 78 (19): 10803–13.  
1268 <https://doi.org/10.1128/jvi.78.19.10803-10813.2004>.
- 1269 Müller, Barbara, Uwe Tessmer, Ulrich Schubert, and Hans-Georg Kräusslich. 2000.  
1270 "Human Immunodeficiency Virus Type 1 Vpr Protein Is Incorporated into the Virion  
1271 in Significantly Smaller Amounts than Gag and Is Phosphorylated in Infected  
1272 Cells." *Journal of Virology* 74 (20): 9727–31.

- 1273 <https://doi.org/10.1128/jvi.74.20.9727-9731.2000>.
- 1274 Müller, Thorsten G., Volkan Sakin, and Barbara Müller. 2019. “A Spotlight on Viruses—  
1275 Application of Click Chemistry to Visualize Virus-Cell Interactions.” *Molecules* 24  
1276 (3). <https://doi.org/10.3390/molecules24030481>.
- 1277 Müller, Thorsten G., Vojtech Zila, Kyra Peters, Sandra Schifferdecker, Mia Stanic,  
1278 Bojana Lucic, Vibor Laketa, Marina Lusic, Barbara Müller, and Hans Georg  
1279 Kräusslich. 2021. “Hiv-1 Uncoating by Release of Viral Cdna from Capsid-like  
1280 Structures in the Nucleus of Infected Cells.” *ELife* 10: 1–32.  
1281 <https://doi.org/10.7554/ELIFE.64776>.
- 1282 Nikić, Ivana, Gemma Estrada Girona, Jun Hee Kang, Giulia Paci, Sofya Mikhaleva,  
1283 Christine Koehler, Nataliia V. Shymanska, Camilla Ventura Santos, Daniel Spitz,  
1284 and Edward A. Lemke. 2016. “Debugging Eukaryotic Genetic Code Expansion for  
1285 Site-Specific Click-PAINT Super-Resolution Microscopy.” *Angewandte Chemie -  
1286 International Edition* 55 (52): 16172–76. <https://doi.org/10.1002/anie.201608284>.
- 1287 Nikić, Ivana, and Edward A. Lemke. 2015. “Genetic Code Expansion Enabled Site-  
1288 Specific Dual-Color Protein Labeling: Superresolution Microscopy and Beyond.”  
1289 *Current Opinion in Chemical Biology* 28: 164–73.  
1290 <https://doi.org/10.1016/j.cbpa.2015.07.021>.
- 1291 Novikova, Mariia, Yulan Zhang, Eric O. Freed, and Ke Peng. 2019. “Multiple Roles of  
1292 HIV-1 Capsid during the Virus Replication Cycle.” *Virologica Sinica* 34 (2): 119–  
1293 34. <https://doi.org/10.1007/s12250-019-00095-3>.
- 1294 Nunzio, Francesca Di, Thomas Fricke, Annarita Miccio, Jose Carlos Valle-Casuso,  
1295 Patricio Perez, Philippe Souque, Ermanno Rizzi, et al. 2013. “Nup153 and Nup98  
1296 Bind the HIV-1 Core and Contribute to the Early Steps of HIV-1 Replication.”  
1297 *Virology* 440 (1): 8–18. <https://doi.org/10.1016/j.virol.2013.02.008>.
- 1298 Paul-Gilloteaux, Perrine, Xavier Heiligenstein, Martin Belle, Marie Charlotte Domart,  
1299 Banafshe Larijani, Lucy Collinson, Graça Raposo, and Jean Salamero. 2017. “EC-  
1300 CLEM: Flexible Multidimensional Registration Software for Correlative  
1301 Microscopies.” *Nature Methods* 14 (2): 102–3.  
1302 <https://doi.org/10.1038/nmeth.4170>.
- 1303 Pear, W. S., G. P. Nolan, M. L. Scott, and D. Baltimore. 1993. “Production of High-Titer  
1304 Helper-Free Retroviruses by Transient Transfection.” *Proceedings of the National*

- 1305 *Academy of Sciences* 90 (18): 8392–96. <https://doi.org/10.1073/pnas.90.18.8392>.
- 1306 Pereira, Cândida F., Paula C. Ellenberg, Kate L. Jones, Tara L. Fernandez, Redmond  
1307 P. Smyth, David J. Hawkes, Marcel Hijnen, et al. 2011. “Labeling of Multiple HIV-  
1308 1 Proteins with the Biarsenical-Tetracysteine System.” *PLoS ONE* 6 (2).  
1309 <https://doi.org/10.1371/journal.pone.0017016>.
- 1310 Permanyer, Marc, Ester Ballana, and José A. Esté. 2010. “Endocytosis of HIV:  
1311 Anything Goes.” *Trends in Microbiology* 18 (12): 543–51.  
1312 <https://doi.org/10.1016/j.tim.2010.09.003>.
- 1313 Pizzato, Massimo, Otto Erlwein, David Bonsall, Stephen Kaye, David Muir, and Myra  
1314 O. McClure. 2009. “A One-Step SYBR Green I-Based Product-Enhanced Reverse  
1315 Transcriptase Assay for the Quantitation of Retroviruses in Cell Culture  
1316 Supernatants.” *Journal of Virological Methods* 156 (1–2): 1–7.  
1317 <https://doi.org/10.1016/j.jviromet.2008.10.012>.
- 1318 Pornillos, Owen, Barbie K. Ganser-Pornillos, Sankaran Banumathi, Yuanzi Hua, and  
1319 Mark Yeager. 2010. “Disulfide Bond Stabilization of the Hexameric Capsomer of  
1320 Human Immunodeficiency Virus.” *Journal of Molecular Biology* 401 (5): 985–95.  
1321 <https://doi.org/10.1016/j.jmb.2010.06.042>.
- 1322 Pornillos, Owen, Barbie K. Ganser-Pornillos, and Mark Yeager. 2011. “Atomic-Level  
1323 Modelling of the HIV Capsid.” *Nature* 469 (7330): 424–27.  
1324 <https://doi.org/10.1038/nature09640>.
- 1325 Price, Amanda J., Adam J. Fletcher, Torsten Schaller, Tom Elliott, Kyeong Eun Lee,  
1326 Vineet N. KewalRamani, Jason W. Chin, Greg J. Towers, and Leo C. James.  
1327 2012. “CPSF6 Defines a Conserved Capsid Interface That Modulates HIV-1  
1328 Replication.” *PLoS Pathogens* 8 (8). <https://doi.org/10.1371/journal.ppat.1002896>.
- 1329 Price, Amanda J., David A. Jacques, William A. McEwan, Adam J. Fletcher, Sebastian  
1330 Essig, Jason W. Chin, Upul D. Halambage, Christopher Aiken, and Leo C. James.  
1331 2014. “Host Cofactors and Pharmacologic Ligands Share an Essential Interface  
1332 in HIV-1 Capsid That Is Lost upon Disassembly.” *PLoS Pathogens* 10 (10).  
1333 <https://doi.org/10.1371/journal.ppat.1004459>.
- 1334 Rankovic, Sanela, Ruben Ramalho, Christopher Aiken, and Itay Rousso. 2018. “PF74  
1335 Reinforces the HIV-1 Capsid To Impair Reverse Transcription-Induced  
1336 Uncoating.” *Journal of Virology* 92 (20). <https://doi.org/10.1128/jvi.00845-18>.

- 1337 Rasaiyaah, Jane, Choon Ping Tan, Adam J. Fletcher, Amanda J. Price, Caroline  
1338 Blondeau, Laura Hilditch, David A. Jacques, et al. 2013. "HIV-1 Evades Innate  
1339 Immune Recognition through Specific Cofactor Recruitment." *Nature* 503 (7476):  
1340 402–5. <https://doi.org/10.1038/nature12769>.
- 1341 Rebensburg, Stephanie V., Guochao Wei, Ross C. Larue, Jared Lindenberger,  
1342 Ashwanth C. Francis, Arun S. Annamalai, James Morrison, et al. 2021. "Sec24C  
1343 Is an HIV-1 Host Dependency Factor Crucial for Virus Replication." *Nature*  
1344 *Microbiology* 6 (4): 435–44. <https://doi.org/10.1038/s41564-021-00868-1>.
- 1345 Rensen, Elena, Florian Mueller, Viviana Scoca, Jyotsana J Parmar, Philippe Souque,  
1346 Christophe Zimmer, and Francesca Di Nunzio. 2021. "Clustering and Reverse  
1347 Transcription of HIV-1 Genomes in Nuclear Niches of Macrophages." *The EMBO*  
1348 *Journal* 40 (1): 1–16. <https://doi.org/10.15252/embj.2020105247>.
- 1349 Rihn, Suzannah J., Sam J. Wilson, Nick J. Loman, Mudathir Alim, Saskia E. Bakker,  
1350 David Bhella, Robert J. Gifford, Frazer J. Rixon, and Paul D. Bieniasz. 2013.  
1351 "Extreme Genetic Fragility of the HIV-1 Capsid." *PLoS Pathogens* 9 (6).  
1352 <https://doi.org/10.1371/journal.ppat.1003461>.
- 1353 Rodriguez, Erik A., Henry A. Lester, and Dennis A. Dougherty. 2007. "Improved Amber  
1354 and Opal Suppressor tRNAs for Incorporation of Unnatural Amino Acids in Vivo.  
1355 Part 1: Minimizing Misacylation." *Rna* 13 (10): 1703–14.  
1356 <https://doi.org/10.1261/rna.666807>.
- 1357 Rubino, Frederick A., Yoon Hyeun Oum, Lakshmi Rajaram, Yanjie Chu, and Isaac S.  
1358 Carrico. 2012. "Chemoselective Modification of Viral Surfaces via Bioorthogonal  
1359 Click Chemistry." *Journal of Visualized Experiments*, no. 66: 1–7.  
1360 <https://doi.org/10.3791/4246>.
- 1361 Sakin, Volkan, Janina Hanne, Jessica Dunder, Maria Anders-Össwein, Vibor Laketa,  
1362 Ivana Nikić, Hans Georg Kräusslich, Edward A. Lemke, and Barbara Müller. 2017.  
1363 "A Versatile Tool for Live-Cell Imaging and Super-Resolution Nanoscopy Studies  
1364 of HIV-1 Env Distribution and Mobility." *Cell Chemical Biology* 24 (5): 635-645.e5.  
1365 <https://doi.org/10.1016/j.chembiol.2017.04.007>.
- 1366 Sattentau, Quentin J. 2010. "Cell-to-Cell Spread of Retroviruses." *Viruses* 2 (6): 1306–  
1367 21. <https://doi.org/10.3390/v2061306>.
- 1368 Schaller, Torsten, Karen E. Ocwieja, Jane Rasaiyaah, Amanda J. Price, Troy L. Brady,

- 1369 Shoshannah L. Roth, Stéphane Hué, et al. 2011. “HIV-1 Capsid-Cyclophilin  
1370 Interactions Determine Nuclear Import Pathway, Integration Targeting and  
1371 Replication Efficiency.” *PLoS Pathogens* 7 (12).  
1372 <https://doi.org/10.1371/journal.ppat.1002439>.
- 1373 Schindelin, Johannes, Ignacio Arganda-Carreras, Erwin Frise, Verena Kaynig, Mark  
1374 Longair, Tobias Pietzsch, Stephan Preibisch, et al. 2012. “Fiji: An Open-Source  
1375 Platform for Biological-Image Analysis.” *Nature Methods* 9 (7): 676–82.  
1376 <https://doi.org/10.1038/nmeth.2019>.
- 1377 Schmied, Wolfgang H., Simon J. Elsässer, Chayasith Uttamapinant, and Jason W.  
1378 Chin. 2014. “Efficient Multisite Unnatural Amino Acid Incorporation in Mammalian  
1379 Cells via Optimized Pyrrolysyl TRNA Synthetase/TRNA Expression and  
1380 Engineered ERF1.” *Journal of the American Chemical Society* 136 (44): 15577–  
1381 83. <https://doi.org/10.1021/ja5069728>.
- 1382 Schorb, Martin, Leander Gaechter, Ori Avinoam, Frank Sieckmann, Mairi Clarke,  
1383 Cecilia Bebeacua, Yury S. Bykov, Andreas F.P. Sonnen, Reinhard Lihl, and John  
1384 A.G. Briggs. 2017. “New Hardware and Workflows for Semi-Automated  
1385 Correlative Cryo-Fluorescence and Cryo-Electron Microscopy/Tomography.”  
1386 *Journal of Structural Biology* 197 (2): 83–93.  
1387 <https://doi.org/10.1016/j.jsb.2016.06.020>.
- 1388 Schwedler, Uta K. von, Kirsten M. Stray, Jennifer E. Garrus, and Wesley I. Sundquist.  
1389 2003. “Functional Surfaces of the Human Immunodeficiency Virus Type 1 Capsid  
1390 Protein.” *Journal of Virology* 77 (9): 5439–50.  
1391 <https://doi.org/10.1128/jvi.77.9.5439-5450.2003>.
- 1392 Selyutina, Anastasia, Mirjana Persaud, Kyeongeun Lee, Vineet KewalRamani, and  
1393 Felipe Diaz-Griffero. 2020. “Nuclear Import of the HIV-1 Core Precedes Reverse  
1394 Transcription and Uncoating.” *Cell Reports* 32 (13): 108201.  
1395 <https://doi.org/10.1016/j.celrep.2020.108201>.
- 1396 Seo, Jai Woong, Elizabeth S. Ingham, Lisa Mahakian, Spencer Tumbale, Bo Wu,  
1397 Sadaf Aghevlian, Shahin Shams, et al. 2020. “Positron Emission Tomography  
1398 Imaging of Novel AAV Capsids Maps Rapid Brain Accumulation.” *Nature*  
1399 *Communications* 11 (1): 1–13. <https://doi.org/10.1038/s41467-020-15818-4>.
- 1400 Shi, J., J. Zhou, V. B. Shah, C. Aiken, and K. Whitby. 2011. “Small-Molecule Inhibition



- 1401 of Human Immunodeficiency Virus Type 1 Infection by Virus Capsid  
1402 Destabilization.” *Journal of Virology* 85 (1): 542–49.  
1403 <https://doi.org/10.1128/jvi.01406-10>.
- 1404 Si, L., H. Xu, X. Zhou, Z. Zhang, Z. Tian, Y. Wang, Y. Wu, et al. 2020. “Erratum:  
1405 Generation of Influenza A Viruses as Live but Replication-Incompetent Virus  
1406 Vaccines (Science DOI: 10.1126/Science.Aah5869).” *Science* 369 (6508): 1–5.  
1407 <https://doi.org/10.1126/SCIENCE.ABE5323>.
- 1408 Smith, Stephen D., Margaret Shatsky, Pamela S. Cohen, Roger Wamke, Michael P.  
1409 Link, and Bertil E. Glader. 1984. “Monoclonal Antibody and Enzymatic Profiles of  
1410 Human Malignant T-Lymphoid Cells and Derived Cell Lines.” *Cancer Research* 44  
1411 (December): 5657–60.
- 1412 Strober, W. 2001. “Trypan Blue Exclusion Test of Cell Viability.” *Current Protocols in*  
1413 *Immunology / Edited by John E. Coligan ... [et Al.]* Appendix 3: 2–3.  
1414 <https://doi.org/10.1002/0471142735.ima03bs21>.
- 1415 Thadani, Nicole N., Christopher Dempsey, Julia Zhao, Sonya M. Vasquez, and  
1416 Junghae Suh. 2018. “Reprogramming the Activatable Peptide Display Function of  
1417 Adeno-Associated Virus Nanoparticles.” *ACS Nano* 12 (2): 1445–54.  
1418 <https://doi.org/10.1021/acsnano.7b07804>.
- 1419 Thenin-Houssier, Suzie, and Susana T Valente. 2016. “HIV-1 Capsid Inhibitors as  
1420 Antiretroviral Agents HHS Public Access.” *Curr HIV Res* 14 (3): 270–82.
- 1421 Toccafondi, Elenia, Daniela Lener, and Matteo Negroni. 2021. “HIV-1 Capsid Core: A  
1422 Bullet to the Heart of the Target Cell.” *Frontiers in Microbiology* 12 (April): 1–17.  
1423 <https://doi.org/10.3389/fmicb.2021.652486>.
- 1424 Uttamapinant, Chayasith, Jonathan D. Howe, Kathrin Lang, Václav Beránek, Lloyd  
1425 Davis, Mohan Mahesh, Nicholas P. Barry, and Jason W. Chin. 2015. “Genetic  
1426 Code Expansion Enables Live-Cell and Super-Resolution Imaging of Site-  
1427 Specifically Labeled Cellular Proteins.” *Journal of the American Chemical Society*  
1428 137 (14): 4602–5. <https://doi.org/10.1021/ja512838z>.
- 1429 Wang, Nanxi, Yue Li, Wei Niu, Ming Sun, Ronald Cerny, Qingsheng Li, and Jiantao  
1430 Guo. 2014. “Construction of a Live-Attenuated HIV-1 Vaccine through Genetic  
1431 Code Expansion.” *Angewandte Chemie International Edition* 53 (19): 4867–71.  
1432 <https://doi.org/10.1002/anie.201402092>.

- 1433 Waskom M, O Botvinnik, J Ostblom, S Lukauskas, P Hobson, DC Gemperline, T  
1434 Augspurger, et al. 2020. “Constantine Evans, Version Mwaskom/Seaborn:  
1435 V0.10.0.” *Zenodo*. <https://doi.org/https://doi.org/10.5281/zenodo.3629446>.
- 1436 Wei, Xiping, Julie M Decker, Hongmei Liu, Zee Zhang, Ramin B Arani, J Michael Kilby,  
1437 Michael S Saag, Xiaoyun Wu, George M Shaw, and John C Kappes. 2002.  
1438 “Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients  
1439 Receiving Fusion Inhibitor (T-20) Monotherapy.” *Antimicrob Agents Chemother* 46  
1440 (6): 1896–1905. <https://doi.org/10.1128/AAC.46.6.1896>.
- 1441 Weigel, P. H., and J. A. Oka. 1981. “Temperature Dependence of Endocytosis  
1442 Mediated by the Asialoglycoprotein Receptor in Isolated Rat Hepatocytes.  
1443 Evidence for Two Potentially Rate-Limiting Steps.” *Journal of Biological Chemistry*  
1444 256 (6): 2615–17. [https://doi.org/10.1016/s0021-9258\(19\)69656-0](https://doi.org/10.1016/s0021-9258(19)69656-0).
- 1445 Xu, Hongzhan, Tamera Franks, Gregory Gibson, Kelly Huber, Nadia Rahm, Caterina  
1446 Strambio De Castillia, Jeremy Luban, et al. 2013. “Evidence for Biphasic  
1447 Uncoating during HIV-1 Infection from a Novel Imaging Assay.” *Retrovirology* 10  
1448 (1): 1–16. <https://doi.org/10.1186/1742-4690-10-70>.
- 1449 Yang, Y., T. Fricke, and F. Diaz-Griffero. 2013. “Inhibition of Reverse Transcriptase  
1450 Activity Increases Stability of the HIV-1 Core.” *Journal of Virology* 87 (1): 683–87.  
1451 <https://doi.org/10.1128/jvi.01228-12>.
- 1452 Yang, Yang, Jeremy Luban, and Felipe Diaz-Griffero. 2014. “The Fate of HIV-1 Capsid:  
1453 A Biochemical Assay for HIV-1 Uncoating.” *Methods in Molecular Biology* 1087:  
1454 29–36. [https://doi.org/10.1007/978-1-62703-670-2\\_3](https://doi.org/10.1007/978-1-62703-670-2_3).
- 1455 Yuan, Zhe, Nanxi Wang, Guobin Kang, Wei Niu, Qingsheng Li, and Jiantao Guo. 2017.  
1456 “Controlling Multicycle Replication of Live-Attenuated HIV-1 Using an Unnatural  
1457 Genetic Switch.” *ACS Synthetic Biology* 6 (4): 721–31.  
1458 <https://doi.org/10.1021/acssynbio.6b00373>.
- 1459 Zhang, Chuanling, Xueying Zhou, Tianzhuo Yao, Zhenyu Tian, and Demin Zhou. 2018.  
1460 “Precision Fluorescent Labeling of an Adeno-Associated Virus Vector to Monitor  
1461 the Viral Infection Pathway.” *Biotechnology Journal* 13 (4): 1–11.  
1462 <https://doi.org/10.1002/biot.201700374>.
- 1463 Zhao, Gongpu, Juan R. Perilla, Ernest L. Yufenyuy, Xin Meng, Bo Chen, Jiying Ning,  
1464 Jinwoo Ahn, et al. 2013. “Mature HIV-1 Capsid Structure by Cryo-Electron

- 1465           Microscopy and All-Atom Molecular Dynamics.” *Nature* 497 (7451): 643–46.  
1466           <https://doi.org/10.1038/nature12162>.
- 1467   Zila, Vojtech, Erica Margiotta, Beata Turoňová, Thorsten G. Müller, Christian E.  
1468   Zimmerli, Simone Mattei, Matteo Allegretti, et al. 2021. “Cone-Shaped HIV-1  
1469   Capsids Are Transported through Intact Nuclear Pores.” *Cell* 184 (4): 1032-  
1470   1046.e18. <https://doi.org/10.1016/j.cell.2021.01.025>.
- 1471   Zila, Vojtech, Thorsten G. Müller, Vibor Laketa, Barbara Müller, and Hans-Georg  
1472   Kräusslich. 2019. “Analysis of CA Content and CPSF6 Dependence of Early HIV-  
1473   1” 10 (6): 1–20.
- 1474   Zurnic Bönisch, Irena, Lieve Dirix, Veerle Lemmens, Doortje Borrenberghs, Flore De  
1475   Wit, Frank Vernailen, Susana Rocha, et al. 2020. “Capsid-Labelled HIV To  
1476   Investigate the Role of Capsid during Nuclear Import and Integration.” Edited by  
1477   Frank Kirchhoff. *Journal of Virology* 94 (7): 1–29.  
1478   <https://doi.org/10.1128/JVI.01024-19>.
- 1479